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Resumo 
O cancro é considerado como um dos maiores problemas de saúde pública (Siegel et al., 
2013). De acordo com a OMS (Organização Mundial de Saúde) o cancro é caracterizado como 
sendo um crescimento anormal de células, podendo desenvolver-se em qualquer parte do corpo 
e alastrar-se para outros órgãos (metástases). Sabe-se ainda que as metástases são 
maioritariamente responsáveis pela morbilidade e mortalidade em doentes com cancro (Seyfried 
and Shelton, 2010). Biologicamente, as células normais podem sofrer transformação maligna, 
sendo em parte esta transformação influenciada pelo microambiente envolvente, onde o tumor e 
as células circundantes estabelecem uma rede funcional (Hanahan and Weinberg, 2011; Serpa 
and Dias, 2011). 
O carcinoma do ovário, é uma grande causa de mortalidade em mulheres, constitui cerca 
de 90% de todas neoplasias malignas do ovário, sendo 3-10% dos casos classificados como 
carcinoma de células claras (OCCC). Cerca de 57-81% de OCCC são diagnosticados nos 
estádios I/II, apresentando-se usualmente como uma massa pélvica. Doentes com CCC 
apresentam um comportamento clínico distinto e com pior prognóstico do que outras neoplasias 
de ovário (Feeley et al., 2001, Bjorkholm et al., 1982; Sorbe et al., 1982; Hogberg et al.,1993). 
Um dos motivos que contribuem para o mau prognóstico em CCC está relacionado com a baixa 
resposta à quimioterapia convencional baseada em cis-platina (Goff et al., 1996). Este tipo 
histológico de carcinoma do ovário deve o nome de células claras a algumas alterações 
morfológicas devidas à acumulação de glicogénio, cuja síntese é regulada pelo HNF1  
(hepatocyte nuclear factor 1 ), o gene central na tumorigénese do CCC (Anglesio et al., 2011). 
 Atualmente sabe-se que as células tumorais poderão apresentar perfis metabólicos 
distintos das células normais (Fuchs and Bode, 2005). Em 1956, Otto Warburg estabeleceu o 
primeiro elo de ligação entre o metabolismo e o cancro através das observações em que as 
células tumorais, mesmo na presença de oxigénio, apresentam um aumento da taxa da glicólise, 
tendo lactato como produto final (Warburg, 1956). Este fenómeno, conhecido como efeito de 
Warburg, coloca a hipótese das células tumorais apresentarem defeitos na mitocôndria, 
responsável pela anulação do ciclo TCA (ou ciclo de Krebs) e consequentemente aumento da 
taxa de glicólise (Vander Heiden et al., 2009), suportando a proliferação celular. Em vários tipos 
de cancro, existe uma associação entre o desregulação e aumento da proliferação 
/sobrevivência celular com um aumento da glicólise aeróbica (Wise and Thompson, 2010), onde 
as fontes de carbono, NADPH e ATP provêm da glucose (Dang, 2012).  
 A glucose e a glutamina são os principais substratos a serem utilizados como fontes de 
ATP e carbono, essenciais à síntese de macromoléculas e ao suporte da proliferação celular. A 
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glucose é responsável pela produção de ribose (fundamental para a síntese de ácidos nucleicos) 
e ATP, através da via das pentoses-fosfato (PPP). A glutamina, o aminoácido mais abundante na 
corrente sanguínea, é considerado um substrato bioenergético e dador de nitrogénio, sendo que 
este aminoácido se revela essencial para a produção de biomassa e energia (Dang, 2012).   
 A neoglucogénese é responsável por cerca de 35-50% da produção total de glucose, 
sendo uma via que requer ATP e NADPH para a conversão de piruvato, lactato e aminoácidos 
(como alanina e glutamina) em glucose de novo. Nos tecidos normais, a neoglucogénese é 
ativada por modificações pós-translacionais ou pela ativação alostérica de enzimas chave 
limitantes, responsáveis pelos eventos moleculares desta via. Geralmente, e de acordo com os 
requisitos metabólicos, os órgãos adaptam a importação, armazenamento, produção e libertação 
de glucose (Oh et al., 2013; Telang et al., 2012). 
 A conversão de piruvato em glucose é considerada como o maior passo da 
neoglucogénese, sendo catalisado por várias enzimas citoplasmáticas e mitocôndriais. Parte dos 
passos da neoglucogénese são catalisadas, no sentido inverso, por enzimas glicolíticas (Quintas 
et al., 2008a).  
 A nível molecular, o piruvato é transportado diretamente do citoplasma para a 
mitocôndria ou, tendo a alanina como percursor, a conversão para piruvato ocorre na 
mitocôndria por transaminação. O piruvato promove a formação de oxoloacetato (OAA) por ação 
da piruvato carboxilase (PC). O transportador carnitina permite o influxo de acetil-CoA na 
mitocôndria, que servirá como um activador essencial de PC. OAA é então reduzido a malato e 
transportado para o citoplasma via transportador malato- -cetoglutarato. No citoplasma, o 
malato é oxidado a OAA e posteriormente a fosfoenolpiruvato (PEP), através de 
fosfoenolpiruvato carboxicinase citosólica (PCK1). Caso o OAA seja convertido diretamente no 
citoplasma, a conversão a PEP é catalisada por fosfoenolpiruvato carboxicinase mitocondrial 
(PCK2). A conversão de fructose-1,6-bifosfato (F1,6BP) em fructose-6-fosfato (F6P) pela 
fructose-1,6-bifosfatase (FBP1) é outra reação irreversível na neoglucogénese (Quintas et al., 
2008b). Posteriormente, glucose-6-fosfatase (G6Pase) é então responsável pela desfosforilação 
de F6P em glucose de novo (Weickert and Pfeiffer, 2006). Por sua vez, a função da enzima 6-
fosfofructo-2-cinase/ fructose-2,6-bifosfatase (PFKFB1) está associada à estimulação da glicólise 
e inibição da neoglucogénese, através da modulação da sua atividade cinase.  
 A glutamina pode ser considerada tão importante como a glucose a nível da produção de 
energia, estando provado que restrições de glutamina ou inibição de enzimas glutaminoliticas 
diminuem a proliferação celular, tanto in vitro como in vivo (Reynolds et al., 2013). 
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 Os passos fundamentais da glutaminólise são a hidrólise de glutamina a glutamato, por 
ação da glutaminase (GA), e a subsequente conversão na mitocôndria do glutamato em -
cetoglutarato ( -KG). -KG pode integrar o ciclo TCA e fornecer os intermediários metabólicos, 
como NADH (Piao et al., 2013). Porém, um metabolismo oxidativo incompleto pode conduzir à 
produção de lactato como produto final. O glutamato pode ainda ser convertido em piruvato pela 
transaminase glutamato-piruvato (GPT) e ser usado como substrato para a neoglucogénese 
(Matés et al., 2013).  
 O glutatião (GSH) é um tripeptido γ-glutamil-cisteinil-glicina, sendo considerado o 
antioxidante mais importante do organismo. GSH, um tiol antioxidante intracelular, atua como 
tampão redox contra o stress oxidativo. Alterações moleculares no sistema GSH em alguns 
tumores pode ser responsável por um aumento da proliferação celular, bem como da resistência 
a drogas (Traverso et al., 2013). 
 A cisteína, um aminoácido utilizado na síntese de GSH, é obtido através da dieta ou da 
transulfuração de outros amino acidos. A transulfuração desempenha um papel importante na 
homeostase de cisteína, sendo mediada em parte pela cis-tationa-gama-ligase (CTH) e 3- 
sulfotransferase de mercaptopiruvato (MPST). CTH é uma enzima citoplasmática e a última 
enzima-chave na via de transulfaração, catalisando a conversão de cistationina (derivada da 
metionina) em cisteína, amónia, 2-oxobutirato e é ainda responsável pela produção de H2S 
(Wang and Hegele, 2003). A CTH tem ainda a capacidade de degradar cisteína, o que conduz à 
produção de lactato (Steegborn, 1999). Por sua vez, MPST é uma enzima envolvida da 
degradação da cisteína, catalisando a transferência de ião enxofre do 3-mercaptopiruvato em 
cianina ou outro tiol (Jurkowska et al., 2011). 
Com base no trabalho científico que vem sendo dedicado na área do metabolismo tumoral 
nesta tese foram definidos dois objectivos principais que foram abordados, utilizando um modelo 
in vitro de OCCC (ES2). O primeiro objectivo é verificar se a neoglucogénese é a fonte de 
glucose, de modo a suportar as necessidades celulares. Investigámos a glutamina, lactato e 
butirato como substrato da neoglucogénese, bem como o perfil de expressão de enzimas chave 
da neoglucogénese (PCK1, PCK2, FBP1 e PFKFB1) e a modulação de características celulares 
como a migração e ciclo celular. O segundo objetivo, que partiu dos resultados obtidos no 
primeiro objetivo, e é clarificar a importância do metabolismo da glutamina e da cisteína e a sua 
influência na síntese de GSH. Pretendemos ainda determinar a relevância da glutamina e 
cisteína na via de síntese de GSH, bem como na progressão tumoral.  
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 O perfil metabólico de ES2 por NMR revelou a presença de glicogénio não marcado, 
assim como também não foi detetada glucose 13C marcada, o que é indicativo de que as células 
não estão a recorrer aos substratos testados como fonte para neoglucogénese.  
 Ao nível das enzimas neoglucogénicas, a acetilação de PCK1 pode ser responsável 
pelos resultados obtidos, onde maiores níveis de expressão de mRNA PCK1 nas condições de 
glucose e butirato não se refletiram num aumento dos níveis proteicos de PCK1, sendo por sua 
vez verificado um aumento dos níveis proteicos de PCK1 na condição lactato e glutamina. Em 
relação ao PCK2, os resultados suportam o descrito na literatura, em que a expressão de PCK2 
permanece praticamente inalterada, sendo porém a sua expressão mais acentuada quando a 
neoglucogénese recorre ao lactato como substrato.   
Os nossos resultados também sugerem que quando as células estão num meio privado de 
glucose os níveis proteicos de FBP1 encontram-se sobre expressos, enquanto que os níveis de 
PFKFB1 permanecem baixos, estimulando a neoglucogénese. No geral, a nível da modulação 
de enzimas envolvidas na neoglucogénese o lactato parece ser o principal substrato. 
 Como referido anteriormente, a alanina também pode ser usada como substrato da 
neoglucogénese, através da conversão de alanina em piruvato, via transaminação. Observámos 
um aumento nos níveis de mRNA de transaminase de alanina (ALT), nas condições glucose, 
lactato e glutamina, o que sugere que a alanina também desempenha um papel importante como 
precursor da neoglucogénese.  
 A análise de NMR permitiu ainda verificar que ES2 são capazes a metabolizar (pelo 
menos parte) o butirato, favorecendo o ciclo celular e a migração.  
 Por sua vez, e de acordo com os resultados obtidos por NMR, a glutamina parece ser o 
substrato mais usado. A análise metabólica revelou que a glutamina foi metabolizada em 
intermediários do ciclo TCA 13C marcados, bem como intermediários 13C marcados para a 
síntese de macromoléculas, o que sugere que a glutamina é metabolizada pela glutaminólise em 
vez de ser utilizada como substrato para a neoglucogénese. Os resultados obtidos tambem 
confirmam que a glutaminólise favorece a migração celular e a progressão do ciclo celular.  
O perfil metabólico de ES2 revelou ainda a presença intracelular de GSH 13C marcado nos 
resíduos de glicina e de glutamato, bem como glicina 13C marcada e glutamato13C livres.  
Observámos que a suplementação de cisteína conduziu a um aumento dos níveis de 
GSH, que se encontra associado à proliferação e ciclo celular. Detetámos ainda que na presença 
de cisteína, ocorre um aumento da síntese GSH, que especulativamente estará associado ao 
decréscimo dos níveis de metionina no interior das células. Assim, o modelo in vitro de OCCC 
revelou que a glutaminólise parece ser relevante, não só ao nível da produção de energia e de 
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manter o potencial redox favorável, mas também está associada à síntese de GSH, sendo por 
sua vez, a síntese de GSH favorecida pela suplementação de cisteína. 
 Resumindo, o metabolismo de aminoácidos revelou-se crucial na tumorigénese de 
OCCC, bem como na resistência a drogas anti tumorais.  
 
 
 
 Palavras-chave: carcinoma de células claras do ovário (OCCC), neoglucogénese, 
glutaminólise, glutatião (GSH), metabolismo tumoral 
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Abstract  
 Tumor cells may exhibit different metabolic profiles compared to normal tissues from 
which they are derived. Those observations gave rise to the new concept that tumorigenesis 
requires metabolic alterations to sustain cell proliferation. Several studies reveal that increased 
cell proliferation is accompanied by increased glucose consumption. In OCCC, a typical 
morphological feature is the accumulation of glycogen in cancer cells cytoplasm this fact allows 
us to raise the stepwise questions: 1) Is glucose the main energy and carbon source used by 
OCCC?; 2) Being glucose a relevant energy and carbon source, can gluconeogenesis be working 
on ovarian clear cell carcinoma?, and 3) If gluconeogenesis is working on, which are the 
gluconeogenic substrates used by ovarian clear cell carcinoma? 
 In the present thesis we try to clarify, in an OCCC in vitro model (ES2) and in a glucose 
privation microenvironment, if gluconeogenesis pathway is working on, in order to support cells 
energy demands. Glutamine, lactate and butyrate were testes as putative gluconeogenesis 
substrates. 
 Metabolic analysis by NMR of ES2 cell line showed the presence of glycogen, 
characteristic of this cell line, though 13C unlabelled, meaning that it was not synthesized from the 
tested substrates. At the same time the tested time points were not enough to clarify if glucose is 
de novo synthesized through gluconeogenesis. Nevertheless, NMR results showed that 
glutaminolysis was the major pathway used to sustain ES2 cell proliferation, with the production 
of TCA intermediates, as well as intermediates for macromolecular synthesis. 
 These findings prompted us to investigate the role of glutaminolysis in OCCC. In NMR 
analysis, we observed the synthesis of glycine and glutamate as well as the synthesis of GSH. 
Gathering cysteine to cells exposed to glutamine, we verified an increase in the synthesis of 
GSH. In cancer, GSH high levels is related to drug resistance which is in agreement with the fact 
that OCCC poor prognosis is also due to resistance to therapy. 
Summing up, amino acids can play a central role in OCCC concerning energy and 
carbon metabolism as well as drug resistance. 
 
  
 Keywords: gluconeogenesis, glutaminolysis, glutathione (GSH), ovary clear cell 
carcinoma (OCCC), tumor metabolism  
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1. Introduction 
 
1.1 Cancer 
Cancer is considered as one of the major public health problem worldwide (Siegel et al., 
2013). According to WHO (World health organization) cancer is characterized by an abnormal 
growth of cells and it can develop in any part of the body and spread to other organs, process 
known as metastasis. Metastasis is the main responsible for morbidity and mortality in cancer 
patients (Seyfried and Shelton, 2010).  
Nowadays because tumor progression is considered a stepwise process several studies 
have been developed to clarify cancer initiation and progression. Biologically, normal cells can 
suffer changes in cell physiology that can lead to malignant tumors. Due to the complexities of 
neoplastic pathways, tumor progression is characterized by hallmarks. The main alterations in 
cell physiology sustain proliferative signaling, insensitivity to growth inhibition, resistance to cell 
death, replicative immortality, angiogenesis and tissue invasion (metastasis) (Hanahan and 
Weinberg, 2011; Seyfried and Shelton, 2010). Additionally, two other important emerging 
hallmarks in cancer were recently raised, reprogramming of energy metabolism and evading 
immune system (Hanahan and Weinberg, 2011). Malignant transformation is always conditioned 
by tumor microenvironment, where tumor and surrounding cells act as a functional network 
(Serpa and Dias, 2011). 
 
1.2 Ovarian clear cell carcinoma (OCCC) 
 Epithelial ovarian cancer make up 90% of all ovarian malignancies (Feeley et al., 2001) 
and is the leading cause of death in women with subtypes: serous (30%–70% of cases), 
endometrioid (10%–20% of cases), mucinous (5%–20% of cases), clear cell (3%–10% of cases), 
and undifferentiated (<1% of cases) carcinomas (Bjorkholm et al., 1982; Sorbe et al., 1982; 
Hogberg et al.,1993). The majority of patients present with stage III and IV disease, for which the 
5-year survival rates are less than 20%, however recent reports showed that 57-81% of clear cell 
carcinoma (CCC) were diagnosed at stage I/II being usually presents as a pelvic mass (Anglesio 
et al., 2011). In Portugal the incidence of ovarian cancer is 10.61/100.000 and 5-year survival rate 
is 40% (Registo Oncológico Regional Sul; ISSN: 1646-6675). Most of the patients with advanced 
disease is not cured by surgery (Kobayashi et al, 2009). 
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 CCC has been recognized by WHO, since 1973 as a distinct histologic type in the 
classification of ovarian tumors (Sugiyama et al., 2000) and despite the low incidence among 
epithelial ovarian cancers, patients with CCC have a distinctly different clinical behaviour with 
significantly worse prognosis than patients with serous carcinoma, the most prevalent type 
(O’Brien et al., 1993; Tammela et al.,1998). One of the reasons why CCC has such a poor 
prognosis is its low response to standard platinum-based chemotherapy (Goff et al., 1996). CCC 
are characterized, in part, by their glycogen containing clear (Anglesio et al., 2011).  
 Substantial histopathology data, that is also supported by epidemiological studies 
(Prowse et al., 2006), provide evidence that endometriosis might be viewed as a pre-neoplastic 
process of CCC and endometrioid carcinomas, possibly via intermediary atypical borderline 
lesions. An atypical glandular change in endometriosis, the so called atypical endometriosis, is 
often present associated with CCC, while it is rare in endometriosis without a neoplasm 
(Czernobilsky e al.,1979; Fukunaga et al., 1997; LaGrenade et al., 1998). Thus, many 
clinicopathological studies have strongly suggested a malignant transformation of endometriosis 
to CCC, but little molecular evidence exists to support the notion that endometriosis is the 
precursor of CCC.  
 In ovarian endometriosis, especially in that associated with a neoplasm, metaplastic 
changes are often observed: eosinophilic metaplasia is the most common, followed by ciliated 
cell, hobnailand mucinous metaplasias. Papillary, squamous and clear cell metaplasias are rare 
(Fukunaga et al., 1998).  
 Molecular genetic alterations play a key role in carcinogenesis and in CCC are 
specifically found mutations of K-RAS and the signaling pathways of HNF-1  (hepatocyte nuclear 
factor , Emi1 (early mitotic inhibitor-1) and mTOR (mammalian target of rapamycin) are 
upregulated (Kobayashi et al, 2009). CCC is also associated with mutations in PIK3CA encoding 
PI3K, being suggested that the PI3K–AKT–mTOR–HIF1  (phosphoinositide 3-kinase, v-akt 
murine thymoma viral oncogene homolog, mammalian target of rapamycin, and hypoxia induced 
factor 1 ) could be useful as therapeutically target. Most recently, it was described that in almost 
half of CCC cases the tumor suppressor gene ARID1 was mutated. The ARID1A gene product is 
part of chromatin remodelling complex, which interacts with various hypoxia and cytokine related 
transcription factors, including HIF1  (Anglesio et al., 2011).  
 Understanding metabolic features and molecular alterations could help to explain many 
of the distinctive prognostic features of the ovarian CCC type. 
 
3 
 
1.3 Cancer Metabolism  
 Metabolism is one of the emerging hallmarks in cancer (Hanahan and Weinberg, 2011) 
and this area has gained more attention from many research groups in the whole world.  
 Nowadays, it is known that tumor cells may have different metabolic profiles (Fuchs and 
Bode, 2005) compared to normal cells. 
 In 1956, Otto Warburg established the first bond between metabolism and cancer, since 
he observed that tumor cells exhibit an increased rate of glycolysis with lactate production even in 
the presence of oxygen (Warburg, 1956), so called aerobic glycolysis. In these observations 
known as Warburg effect, Warburg hypothesized that cancer cells have a defect in mitochondria 
that was responsible for the abrogation of tricarboxylic acid (TCA) cycle and consequent 
increased rate of glycolysis (Vander Heiden et al., 2009) to sustain metabolic requirements for 
cell proliferation. Warburg effect gave rise to a new concept that tumorigenesis require metabolic 
adaptation (Deberardinis et al., 2008).  
 Energy metabolism in normal cells, in the presence of oxygen, is characterized by 
cytoplasmic glycolysis (the precursors result from glucose oxidation), TCA acid cycle and electron 
transport chain (ETC)/oxidative phosphorylation (OXPHOS). OXPHOS pathway is an efficient 
process to generate 32 moles of ddenosine triphosphate (ATP)/mole from 1 mole of glucose 
(Ganapathy et al., 2009a).  
 When cells are under hypoxic conditions the mitochondrial function is suppressed. 
Instead, cells have to use an alternative pathway to produce energy, that is the aerobic glycolysis 
with lactate as final product (Ganapathy et al., 2009). In many cancers there is an association 
between the deregulated and enhanced cell proliferation and survival with an increase in aerobic 
glycolysis (Wise and Thompson, 2010) where carbon skeletons, NADPH and ATP are produced 
by glycolysis (Dang, 2012). Cells using aerobic glycolysis have higher levels of ATP/ adenosine 
diphosphate (ADP) and NADH/NAD+. In normal cells alterations on those levels can impair growth 
and apoptosis (Vander Heiden et al., 2009). 
 Many authors thought and defend that genomic mutability acquired during tumor 
progression lead to metabolic modifications and in some cases to the Warburg effect (Kim and 
Dang, 2006; Seyfried and Shelton, 2010). Studies in energy metabolism of cancer cells have 
demonstrated that there was a link between alteration in several oncogenes/ tumor suppressor 
genes and the regulation of metabolic processes (Wise and Thompson, 2010). These alterations 
could lead to genomic instability and DNA damage, having the potential to increased mutability of 
cells. Those pre-malignant cells start to display hallmarks of cancer (Figure 1) (Seyfried and 
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Shelton, 2010). In most cases of malignant transformation the bioenergetic demands are 
supported, in part, by some oncogenic mutations responsible for an increase in nutrients uptake 
(Vander Heiden et al., 2009).  
 Cell metabolism can trigger the production of toxic products like reactive oxygen species 
(ROS). Increase in ROS production or abolishment/decrease in detoxification can lead to 
membrane damage and mutagenesis which can result in malignant transformation (Dang, 2012). 
Increased ROS levels induce alterations in pathways, like pentose phosphate pathway (PPP). 
ROS oxidizes and consequently inactivates pyruvate kinase isozymes M2 (PKM2) responsible for 
the last step in glycolysis by modifying a critical sulphydryl group of PKM2 (Dang, 2012). Inactive 
PKM2 decreases the rate of PPP, reflecting in a NADPH reduction and hence in a decrease of 
glutathione reductase (GSH-R) responsible for glutathione (GSH) reduction (antioxidant 
compound) (Dhivya, 2012).  
 
 
 
 
 
1.3.1 Oncogenic alterations   
During malignant transformation, mutations/overexpression of oncogenes and loss of 
tumor suppressor genes can lead to alterations in metabolism, namely a switch from aerobic 
respiration to aerobic glycolysis (Warburg effect) (Dang, 2012).  
In most cases, oncogenes control mitosis and cell survival by affecting steps on signaling 
mechanism namely by increasing signals in a cascade similar to “tyrosine kinase receptor” (RTK) 
(Israël and Schwartz, 2011a). One of the influences of oncogenes and tumor suppressor genes 
mutations is alterations in the production of ribose-5-phosphate (R5P), essential for nucleotide 
biosynthesis (Deberardinis et al., 2008).   
Figure 1 – Cell proliferation and survival is 
regulated by some pathways that can be 
abrogated or altered leading to malignant 
transformation. Cancer cells have the 
potential to proliferate beyond the limitations 
of normal cells. Some cells can resist to this 
alterations by blocking clonal cancer 
expansion and neoplastic evolution.  
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Tumor suppressors are associated with DNA repair. Tumor suppressor p53 target TP53-
induced glycolysis and apoptosis regulator (TIGAR) that suppresses glycolysis by inhibiting 
activation of phosphofructokinase-1 (PFK1). This enzyme increase substrate availability to 
oxidative pathway as NADPH and R5P generation, via PPP.  In tumors p53 deficiency is 
frequent, leading to glycolysis triggering and PPP impair.  
Cancer cells mostly choose an alternative mechanism to sustain cell R5P requirements. 
Tumors may express pyruvate kinase-2 (PKM2), a glycolytic enzyme that stimulates PPP, 
inducing R5P production through a non-oxidative pathway (Deberardinis et al., 2008).  
Protein kinase B (AKT) is another oncogene associated with tumorigenesis. AKT encodes 
serine-threonine kinase protein responsible for the regulation of glucose uptake and aerobic 
glycolysis. This oncogene mobilizes glucose transporters to the cell surface, increasing the levels 
of glucose import and activating hexokinase 2 (HK2) which is responsible for glucose 
phosphorylation and intracellular trap. Additionally, the oncogene MYC is also associated to 
tumorigenesis triggering direct activation on glycolysis (Kim and Dang, 2006).  
 
1.3.2 Nutrients uptake  
 
 Cancer cells can supply metabolites requirements due to the expression of nutrient 
transporters (Fuchs and Bode, 2005). In normal cells the uptake of nutrients from their 
environment is stimulated by growth factors avoiding uncontrolled proliferation (Vander Heiden et 
al., 2009).  
 Glucose is one of the most important nutrient for cell mass production and cell 
proliferation. This compound is responsible for carbon and hydrogen supply but not nitrogen, 
phosphorus and sulfur that are also need for cell development. Those elements essentials to 
build new cells are supplied by other nutrients, namely amino acids as glutamine (Dang, 2012). 
 Glucose, amino acids, fatty acids and vitamins are essential nutrients required for cell 
survival and proliferation. In cancer cells, nutrient transporters are up-regulated or altered in 
plasma membrane (Ganapathy et al., 2009). Amino acid transporters support metabolic needs 
and are essential requirements for production of nucleotides, cellular nitrogen and proteins 
(Ganapathy et al., 2009; Mazurek and Eigebbrodt, 2003).  
 Cell growth is regulated in part by mammalian target of rapamycin (mTOR) mTORC1/C2 
complexes being activated by amino acids and growth factors. mTOR is a regulatory-associated 
protein which is located downstream of PI3K and AKT and that can also be activated by insulin-
like growth factor, oxidative stress and nutrients, essentially leucine that is imported in exchange 
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by glutamine. (Fuchs and Bode, 2005b; Laplante et al., 2010; Wise and Thompson, 2010). 
Leucine mobilizes mTORC1 to lysosomal membrane by G proteins turning it active to 
phosphorylate substrates that will be responsible for stimulating translation, ribosome biogenesis, 
cell growth and autophagy inhibition. Growth signals are transmitted by RTK to activate mTORC2 
and PI3K. mTORC2 and PI3K stimulate AKT initiating the pathway responsible for an increase in 
metabolism, survival and proliferation. This process is also responsible for a transcriptional 
program, namely in genes such as MYC. AKT activated by mTORC2 can also influence mTORC1 
(Figure 2) (Dang, 2012; Sabatini, 2006).  
 
 
Figure 2: mTOR pathway - Glutamine (Gln) enters in the cell by neutral amino acid transporter (ASC2) membrane 
transporter, allowing leucine (Leu) influx by human L-type amino acid transporter 1 (LAT1). Leu actives mTORC1 
(red) and in mitochondria gln realize TCA cycle with GTP production (blue). Hypoxic genes (HIF1α), DNA damage 
genes (p53) and energy depletion genes (AMPK) phosphorylated a negative regulator of mTORC1 (tuberous 
sclerosis complex - TSC1/2), overturning Rheb (orange arrows) and leading to mTORC1 activation. Ras inhibits 
mTORC1 by suppressing TSC1/2 (green arrows). RTK receive growth factor signaling activating PI3K and mTORC2. 
PI3K (also stimulated by Ras) and AKT induce mTORC2 (grey and dark orange arrows) resulting in myc activation 
that stimulate glycolysis and glutaminolysis. mTORC1 can also be activated by AKT expression. 
 
1.4 Glucose and Glutamine  
 
 Glucose and glutamine are two major substrates for cell proliferation essentially because 
there are the two main sources of ATP and carbon skeletons required for macromolecules 
7 
 
synthesis. Glucose is responsible for ribose (fundamental for nucleic acid synthesis) and ATP 
production through pentose phosphate pathway (PPP). Glutamine that is the most abundant 
amino acid in bloodstream and the main bioenergetic substrate and nitrogen donnor (Dang, 
2012).    
 In normal conditions glucose enters the cells through facilitative transport where is 
converted by glucose phosphorylation in hexose phosphate. This compound is phosphorylated 
and converted into glycerol, essential for lipid synthesis or transformed into pyruvate (Dang, 
2012).   
 Proliferating cells in hypoxia and under glucose limitations reprogramme glutamine 
catabolism by TCA cycle to increase lipid synthesis. In hypoxia and in unrestricted glucose 
conditions the conversion of pyruvate to acetyl- CoA is switch to the conversion of pyruvate into 
lactate (Figure 3). This process is mediated by the inhibition of pyruvate dehydrogenase due the 
activation of pyruvate dehydrogenase kinase (PDK1) induced by hypoxia inducible factor (HIF1 ) 
(Dang, 2012). HIF1  actives target genes like PDK1, consequently pyruvate is not used in 
mitochondrial oxidation, activating cellular responses to metabolic stresses.  
 Glutaminolysis, that is also increased in some tumors, is considered as a glutamate 
store. Glutamine is converted into glutamate by glutaminase, generating NAD+ that is essential 
for glycolysis (Israël and Schwartz, 2011b; Dang, 2012).  
 
 
 
Figure 3: Pyruvate resulting from glycolysis can 
converted into acetyl-CoA in TCA cycle, increasing 
the levels of OAA and citrate which consequently 
permits an energy gain. Pyruvate can also be 
converted in lactate. Glutamine enters in TCA 
through conversion into glutamate. TCA can be 
independent of glucose or responsible for lipid 
synthesis via reductive carboxylation.  
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 Decrease in glucose and glutamine levels lead to a reduction in ATP levels and an 
increase in AMP/ATP ratio. AMP-activated protein kinase (AMPK) is sensitive to AMP/ATP and 
have the potential to phosphorylate substrates to increase energy production and to decrease the 
activity of pathways that consume energy. On the other hand, AMPK that recycles cellular 
components for energy production, inhibits Acetyl-CoA carboxylase by phosphorylation and also 
induces mTOR pathway (Dang, 2012).  
 
 
Figure 4: Cells have to duplicate genomic material, proteins and lipids to support essential requirements for 
replicative division, enhanced in tumors. Increase in glucose and glutamine influx is common in tumorigenesis. 
Glucose is converted into pyruvate with lactate production. Part of the pyruvate goes to TCA cycle in mitochondria 
resulting in citrate and aspartate production (TCA intermediates). Citrate is involved in fatty acids biosynthesis and 
asp in nucleotides production. Glucose is also responsible for amino acid precursors such as glycine and R5P. 
Glutamine also enters the mitochondria where is converted into glutamate that origin KG, a TCA precursor. PRPP: 
phosphoribosyl pyrophosphate. Adapted from DeBerardinis et al., 2008 
 
1.4.1 Gluconeogenesis and Glycolysis   
 
 Some enzymes are common to gluconeogenesis and glycolysis however working on 
different directions. Others are exclusive to gluconeogenesis or glycolysis, such as pyruvate 
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kinase (PK), in glycolysis, which is responsible for the conversion of phosphoenolpyruvate (PEP) 
into pyruvate, being transfered to mitochondria as acetyl- CoA and entering in TCA cycle and 
oxidative metabolism (Israël and Schwartz, 2011b).  
 Cells have an adaptative response to their metabolic needs, for example in starvation 
glycolytic enzymes, such as PK and pyruvate dehydrogenase (PDH) are phosphorylated and 
inactivated due to cAMP- glucagon- adrenergic signals. The inactivation of these enzymes leads 
to the interconnection break between glycolysis and TCA cycle and stops the oxidative 
metabolism (Israël and Schwartz, 2011b).  
 In normal cells, citrate synthase (CS) is inhibited by an increase in NADPH levels 
whereas in cancer cells this enzyme is active and overexpressed. Overexpression of CS 
increases levels of acetyl-CoA, oxoloacetate (OAA) and citrate and decrease levels of ketone 
bodies. On the other hand, low levels of ketone bodies are responsible for the decrease in the 
stimulation of pyruvate carboxylase (PC). Decreases in PC activity leads to more pyruvate to be 
“processed” by lactate dehydrogenase subunit A (LDHA). Overexpression of LDHA increase the 
levels of lactate and NAD+, essential and required for glycolysis (Israël and Schwartz, 2011a, 
2011b). This alternative pathway in tumors can explain, at least in part, the previously referred 
Warburg effect.   
 
 1.4.1.1 Gluconeogenesis 
  
 Gluconeogenesis accounts for 35-50% of total basal glucose production, being regulated 
in part by the interaction of different regulatory mechanisms discussed later on. Glucose is used 
by the majority of the tissues as energy source, being its production, in physiological conditions, 
restricted to the liver, kidneys and some cells in small intestine. Glucose-6-phosphatase 
(G6Pase) is an essential gluconeogenic enzyme and its expression is limited to these organs 
(Corssmit et al., 2001).  
 Glucose biosynthesis via gluconeogenesis requires ATP and NADPH for the conversion 
of pyruvate, lactate and amino acids, as glutamine and alanine, into the final product, de novo 
glucose. Lactate is a common substrate for kidney and liver whereas alanine conversion to 
glucose takes place almost exclusively in liver. In healthy humans is estimated that the 
contribution of lactate for total glucose production is approximately 15% (Corssmit et al., 2001).  
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1.4.1.1.1 Molecular regulators  
 
  In normal tissues, gluconeogenesis is activated by pos-translational modifications or by 
allosteric activation of key-rate limiting enzymes, responsible for the molecular events of this 
pathway. Liver is the most active organ for gluconeogenesis and in physiological conditions this 
pathway contributes to the maintenance of glucose homeostasis, controlling glucose levels 
between bloodstream and hepatocytes. In general and according to the metabolic requirements, 
this organ adjusts the regulation of glucose uptake and storage, as well as its production and 
release (Oh et al., 2013; Telang et al., 2012). Hormones have an important physiological role in 
the regulation of metabolism. Insulin inhibits gluconeogenesis while other hormones like glucagon 
and glucocorticoids induce the synthesis of de novo glucose by regulating the expression of 
glycolytic enzymes. Glucose concentration have also been reported to directly suppress the 
expression of the gene phosphoenolpyruvate carboxykinase cytosolic (PCK1) and 
gluconeogenesis (Weickert and Pfeiffer, 2006).  
 Additionally stress hormone cortisol is responsible for the initiation of signaling cascades 
that activate transcriptional regulators like cyclic adenosine monophosphate (cAMP), responsive 
element binding protein (CREB), nuclear glucocorticoids receptors (GR), estrogen receptor 
related gamma (ERR  and forkhead box class O (FoxOs) transcription factors. These 
transcriptional regulators promote the expression of glucogenic enzymes, namely PCK1 and 
G6Pase (Oh et al., 2013; Weickert and Pfeiffer, 2006).  
  
1.4.1.1.2  Molecular pathway  
  The conversion of pyruvate into glucose is the major step of gluconeogenesis that is 
catalyzed by the action of diverse cytoplasmic and mitochondrial enzymes. Some glycogenic 
enzymes catalyze steps of gluconeogenesis (seven reactions in ten), in a reversible way (Figure 
5).  
Pyruvate is transported directly from cytoplasm to mitochondria or having alanine as a 
precursor, which conversion occurs in the mitochondria by transamination. Pyruvate promotes the 
OAA formation by the action of PC. Carnitine transporter permits the influx of Acytil-CoA in 
mitochondria, being an essential activator of PC due to the carboxylation of a biotin residue that 
occurs exclusively in the presence of acytil-CoA. OAA is then reduced to malate being 
transported to cytoplasm by malate- -ketoglutarate transporter. In cytoplasm, malate is oxidized 
to OAA and PEP through PCK1.  Nevertheless, if OAA is exported directly from the cytoplasm 
this reaction is catalyzed by phosphoenolpyruvate carboxykinase mitochondrial (PCK2), as it will 
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be depicted latter on.  Another irreversible reaction in gluconeogenesis is the conversion of 
fructose-1, 6-biphosphate (F1,6BP) in fructose-6-phosphate (F6P), that is catalyze by fructose-
1,6-bisphosphatase (FBP1) (Quintas et al., 2008a). G6Pase is then responsible for the 
dephosphorylation of glucose 6-phosphate (Glc-6-P) to de novo glucose (Figure 5) (Weickert and 
Pfeiffer, 2006).  
 
 
 
 
Figure 5: Gluconeogenesis Pathway - Pyruvate provided by alanine transamination or lactate dehydrogenation is 
converted to OAA by PC envolving the hydrolysis of one ATP molecule. Pyruvate from lactate, enters mitochondria 
by mitochondrial pyruvate transporter (MPC) (orange arrows). Acytil-CoA gets in mitochondria by carnitine 
transporter (blue arrows). OAA is reduced into malate and exported from mitochondrial by malate -ketoglutarate 
transporter (green arrows) while OAA from lactate is directly converted into PEP by PCK2 and exported for 
cytoplasm. In cytoplasm, malate is oxidized to OAA and then converted to PEP by the action of PCK1. The 
conversion of PEP in 2- phosphoglycerate , 3- phosphoglycerate  and 1, 3 - bisphosphoglycerate are reversible 
reactions with glycolysis. 1, 3 – bisphosphoglycerate are then converted  to frt-1,6-BP by FBP1. Frt-1,6-BP generates 
Frt-6-P in a reversible way. G-6-P by the action of G6Pase origin glucose, the final product. Adapted from Quintas et 
al., 2008. 
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1.4.1.1.3 Key enzymes   
The enzyme 6-phosphofructo-2-kinase/ fructose-2, 6-bisphosphatase (PFKFB1) has its 
function associated with the promotion of glycolysis and the inhibition of gluconeogenesis through 
the modulation of their kinase activity. Although, gluconeogenesis is also regulated by others 
rate-limiting enzymes, the PCK1 and G6Pase (Noguchi et al., 2013). The expression of PCK1 
and G6Pase genes is regulated at the transcriptional level by a complex network of transcription 
factors and cofactors including CREB, HNF-4α and FoxO1 (Kim et al., 2011). Also the activation 
of AKT-signaling pathway modulates gluconeogenesis, leading to the downregulation of PCK1 
and G6Pase proteins and hence the suppression of gluconeogenesis (Noguchi et al., 2013). 
Those enzymes could also be activated by allosteric alterations, due to the relative proportion of 
AMP and ATP (Oh et al., 2013).  
 Alanine aminotransferase (ALT) plays an important role in gluconeogenesis from alanine, 
being an increase in ALT activity associated with higher rates of gluconeogenic pathway (Moraes-
Silva et al., 2012). Previous studies had reported that gluconeogenesis from alanine was 
increased in cancer patients  (Moreira et al., 2013). ALT catalyses the conversion of alanine into 
pyruvate and then converted into OAA by the action of PC, involving the hydrolysis of one ATP 
molecule (Quintas et al., 2008a).  
 PCK1 includes two enzymes with different intracellular locations, the cytosolic and 
mitochondrial forms that are encoded by two nuclear genes (Greenfield et al., 2000). In human 
60% of PEPCK is confined to mitochondria while 40% to cytosol (Hanson and Garber, 1972). 
PCK1, also known as PEPCK, is regulated by nutritional and hormonal stimuli at the 
transcriptional level, whereas mitochondrial form, also referred as PCK2, remains relatively 
unaltered appearing to be constitutive. Shifts in the ratio of PCK1 to PCK2 during feed restrictions 
or diabetes has been reported. PCK1 is required for gluconeogenesis from amino acids and 
PCK2 is more suited to gluconeogenesis from lactate. Due to the stoichiometry of 
gluconeogenesis, PEP formed from pyruvate and some amino acids requires the independent 
synthesis of NADH in cytosol (Agca et al., 2002).  The reaction of conversion of lactate into 
pyruvate, in cytoplasm, is promoted by the enzyme lactate dehydrogenase B chain (LDH-B) with 
NADH production. Thereby the production of NADH by malate oxidation is not necessary and the 
pyruvate is directly converted into PEP by PCK2, inside mitochondria. PEP is exported to 
cytoplasm to sustain gluconeogenesis (Quintas et al., 2008a).  
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FBP1 is a magnesium (Mg2+) dependent enzyme that promote the irreversible hydrolysis 
of carbon 1 (C1) from fructose-1, 6-biphosphate. This reaction results in the release of an 
inorganic phosphate and F6P (Quintas et al., 2008a).  
 The molecular function of PFKFB1 is to synthesize fructose-2, 6- bisphosphate (F 2, 6 
BP) from F6P. PFKFB1 activates PFK1, an essential and irreversible enzyme on controlling the 
glycolytic pathway. PFKFB1 expression could be stimulate by a decrease in ATP levels and by 
the abundance of energy stores leading to an enhancement in glycolytic flux and cell growth. 
When ATP levels and energy are abundant to supply cell requirements, ATP directly activates 
PFK1 by negative feedback. In cancer, an increase in PFKFB1 levels is commonly caused by an 
overexpression of HIF-1α, myc and activation of ras or loss of p53 (Yalcin et al., 2009).    
 G6Pase is responsible for the last step of gluconeogenesis, with glucose as final product. 
This enzyme promotes phosphate hydrolysis, in a Mg2+ dependent reaction. Glucose is then 
transported to bloodstream until target organs (Quintas et al., 2008a).   
 
1.4.2 Glutaminolysis 
 Glutamine is a non-essential amino acid, although is a required nutrient source to 
maintain rapid cell division of cancer cells, being an increase of glutamine uptake and 
glutaminolysis associated with carcinogenesis (Matés et al., 2013). This non essential amino acid 
provides the anaplerotic carbon in mitochondrial TCA cycle as well as nitrogen and carbon 
skeletons. Glutamine is also used for glutathione (GSH) synthesis, fatty acids production, protein 
and  nucleotide biosynthesis (Dang, 2010; Reynolds et al., 2013).  
 Since 1990 it has been reported that in cancer cells the activity of glutaminase is similar 
or higher than hexokinase from glycolysis. This result suggested that glutamine may be as 
important as glucose for energy generation (Board et al., 1990).  More recently, it had been 
proved that glutamine restrictions or inhibitors of glutaminolytic enzymes decrease cell 
proliferation in vitro and in vivo (Reynolds et al., 2013).  
 MYC oncogene and tumor suppressor gene TP53 contribute to the glutamine uptake and 
glutaminolysis. MYC is responsible for inducing glutaminolysis through the activation of -catenin 
being glutamine synthetase a direct target of activated -catenin. Recently, dysfunctional 
retinoblastoma (Rb) cascate, besides promoting loss of proliferative control, it had been proposed 
to directly regulate the uptake and conversion of glutamine into anabolic precursors, required for 
neoplastic cell growth and survival (Dang, 2010; Reynolds et al., 2013).  
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1.4.2.1 Molecular pathway  
 The fundamental steps in glutaminolysis is the hydrolysis of glutamine into glutamate by 
glutaminase (GA) and subsequently conversion into -KG in mitochondria. -KG can enter TCA 
cycle and replenish the metabolic intermediates such as NADH (Piao et al., 2013).  
 GA localizes in the inner mitochondrial membrane, being responsible for the hydrolysis of 
the -amino group of glutamine, forming glutamate and ammonia. Ammonia could be used to 
form carbamoyl phosphate or may diffuse from the mitochondria and the cell. Glutamate can 
suffer deamination by glutamate dehydrogenase (GLUD1) forming -ketoglutarate ( -KG) 
entering in TCA cycle for energy production. Glutamate can also be converted into pyruvate by 
glutamate pyruvate transaminase (GPT) (Figure 5). Hence, glutamate catabolism in TCA cycle 
produces reducing equivalents for the generation of ROS by OXPHOS (Matés et al., 2013).  
 As mentioned above glutaminolysis enables NADH production through TCA cycle; 
however an incomplete oxidative metabolism can lead to lactate as end product. Zagari et al. 
(2013) reported that glutamine has an important role in modulating the initial lactate production 
being this phenomenon observed in vitro. In this process, lactate production involves the efflux of 
malate from mitochondria and its conversion into pyruvate and finally into lactate, with NADH 
production. However, when glutamine is depleted, lactate is consumed to “refuel” the TCA cycle 
(Board et al., 1990; Zagari et al., 2013). The highest percentage of consumed glutamine is 
metabolized into molecules such as lactate (Matés et al., 2013).   
 
1.4.2.2 Key enzymes  
Glutamine could be lysed by mitochondrial GA into glutamate and ammonia and some 
cancer cells can survive without glutamine when provided with ammonia as nitrogen source. 
Cancer cells can also have an increase in glutamate-ammonia ligase (GLUL), that is responsible 
for the conversion of glutamate and ammonia into glutamine (Dang, 2010).  
GA is a central enzyme is glutamine catabolism. Glutamate, from glutamine catabolism, is 
involved in mitochondrial bioenergetic via TCA cycle responsible for ATP production. GA family is 
composed by two isoforms, GLS and GLS2, encoded by separate genes. Only GLS enzyme is 
associated and increased in cancer cells whereas GLS2 plays a critical role in protection against 
oxidative stress by up-regulating glutathione levels. Therefore GLS up-regulation is linked with 
increased rates of proliferation while GLS2 is associated with resting, non-proliferative or 
quiescent cell states, working as a tumor suppressor (Matés et al., 2013).   
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Figure 6:  Glutaminolysis - Glutamine enters in the cell by cytoplasmic transporter such ASCT2 or solute carrier 
family 38 (SN2). Glutamine is transferred to mitochondria where is hydrolyzed by GLS (an isoform of GA) forming 
glutamate and ammonia (NH3) (blue arrows). If glutamine is hydrolyzed by GLS2 (another GA isoform), in similarity to 
GLS reaction originates glutamate and also NH3 but glutamate is responsible for glutathione production, a potent 
antioxidant agent (orange arrows). NH3 and glutamate can be used to novo glutamine by the action of glutamine 
synthetase (green arrows). Glutamate is converted into -KG (alanine production by glutamate-pyruvate 
transaminase – GPT is also possible), entering in TCA cycle (blue arrows). If an incomplete oxidative metabolism 
occurs, malate (a TCA cycle intermediate) is exported from mitochondria where originates pyruvate (by the action of 
malate dehydrogenase –NAD ME) and then lac (by LDHA). Lac is exported from cell through monocarboxylate 
transporter 4 (MCT4) (red arrows). 
 
 
1.5 Glutathione (GSH) 
GSH which is a tripeptide gamma-glutamyl-cysteinyl-glycine is a major free radical 
scavenger, immune booster and detoxifier of the body. Can be found in reduced (GSH) and 
oxidized forms (GSSG) (Figure 6) being the cysteine residue responsible for the readily oxidation 
of GSH to GSSH by electrophilic substances as free radicals and ROS. GSH is the major thiol-
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containing endogenous antioxidant and acts as a redox buffer against  several sources of 
oxidative stress (Dhivya, 2012; Matés et al., 2013). Quotient [GSH]: [GSSH] is used as indicator 
of the redox state of cells being values >10 verified under normal physiological conditions 
(Quintas et al., 2008b) where glutathione disulfide (GSSH) levels accounts for less than 1% of the 
intracellular content. In the cytosol, 85-90% of the GSH is freely distributed, although it can also 
be compartmentalized in different organelles, like mitochondria, peroxisomes and nuclear matrix 
(Singh et al., 2012).   
 
 
 
 
 
GSH provides greater antioxidant protection participating directly in ROS destruction and 
plays a critical role in carcinogenesis inhibition (Dhivya, 2012). Aerobic glycolysis, which is a 
metabolic characteristic of some tumors, is responsible for the production of ROS where their 
increase (higher than physiological conditions) is associated with higher levels of oxidative stress 
that lead to cell injury and death.  Increase in ROS levels have also been implicated in cancer 
development and progression and molecular alterations in the components of the GSH system 
and in various tumors can lead to an increased survival and tumor drug resistance (Traverso et 
al., 2013). ROS formation and GSH depletion may also cause mitochondrial dysfunction and 
subsequent cytochrome c release triggering cell viability (Han et al., 2010).  
GSH, beyond detoxification and cellular protection from damage by free radicals, peroxides 
and toxins, has also other essentials functions in metabolic and biochemical reactions, such as 
DNA synthesis and repair, protein and prostaglandins synthesis, amino acid transporters and 
enzymes activation (Dhivya, 2012). GSH is also implicated in essential functions like signal 
transduction, molecular regulation of cell physiology and regulation of apoptosis (Estrela et al., 
2006; Singh et al., 2012).   
Figure 7: Gluthatione formation - -glutamyl cysteine 
synthease (GCL) that catalyzes the ligation of glu with 
cysteine (cys) through ATP activation. Glutathione 
synthetase (GSS) allowing gly ligation and glutathione 
(GSH) production. GSH is easily oxidized into GSSH, an 
inactive form. GSSH can be regenerated by glutathione 
reductase. Adapted from Quintas et al., 2008. 
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1.6 Cysteine homeostasis  
 Cysteine is a semi-essential amino acid, provided through diet or trans-sulfuration 
pathway. High cysteine concentrations in human plasma could be cytotoxic, leading to 
pathologies like pre-eclampsia, premature delivery, low birth weight and cardiovascular diseases. 
Cysteine is used to GSH, taurine or inorganic sulphate synthesis and in similarity to GSH, taurine 
a most abundant free amino acid in humans, also acts as an endogenous antioxidant (Ishii et al., 
2004).  
 Trans-sulfuration pathway is mediated, in part, by cystathionine gamma-lyase (CTH) and 
3-mercaptopyruvate sulfurtransferase (MPST). CTH, a cytoplasmic enzyme and the last key 
enzyme in trans-sulfuration pathway, catalyze the conversion of cystathionine (derived from 
methionine) to cysteine, ammonia and 2-oxobutyrate. CTH protein can also accept homocysteine 
(HCYS) as substrate and could be responsible for hydrogen sulfide (H2S) production (Wang and 
Hegele, 2003). In literature, CTH was also characterized as being able to degradate cysteine, 
leading to pyruvate production (Steegborn, 1999). 
 Under physiological conditions, oxidative stress induces an increase of HCYS flux 
through the trans-sulfuration pathway. As results cystathionine levels, a direct substrate of CTH, 
increase leading to an increase of downstream metabolites of CTH, cysteine and GSH. Then, 
GSH permits the maintenance of cellular redox status (Jurkowska et al., 2011).  
 MPST is an enzyme involved in cysteine degradation, catalyzing the transfer of sulfur ion 
from 3-mercaptopyruvate to cyanine or other thiol compound, yielding sulfane sulfur. In cancer 
had been reported a decrease in MPST activity leading to a reduction of non-oxidative 
metabolism of cysteine and consequently to a sulfane sulfur deficiency. Insufficient levels of 
sulfane sulfur induce an uncontrollable action of enzymes inactivated by sulfane sulfur 
(Jurkowska et al., 2011).  
 As referred, CTH and MPST, plays an important role in cysteine homeostasis, GSH-
taurine synthesis and H2S production. In humans, CTH mutations and deficiency levels causes 
cystathionimaemia, a disease characterized by accumulation of cystathionine in blood, tissue and 
urine with no consistent clinical consequences (Ishii et al., 2004; Jurkowska et al., 2011; Kraus et 
al., 2009). 
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2. Aims  
The first main objective of this thesis is to understand if gluconeogenesis is a source of 
glucose supply in ovarian clear cell carcinoma (OCCC). This main objective is subdivided in 3 
specific aims: 1) To verify if gluconeogenesis is working on OCCC by testing glutamine, lactate  
and butyrate as gluconeogenic substrates; 2); To evaluate the expression profile of key 
gluconeogenic enzymes (PCK1, PKC2, FBP1 and PFKF1) under these gluconeogenic substrates 
exposure; 3) To evaluate the modulation of cell features such as migration, cell viability and cell 
cycle in the presence of these gluconeogenic substrates.  
The second main objective of this thesis came up from the evaluation of the results 
obtained from the first main objective accomplishment; and it is to clarify the role of glutamine and 
cysteine metabolism in OCCC. This objective is accomplished through 4 specific aims: 1) To 
verify if glutaminolysis is working on OCCC; 2) To evaluated cysteine degradation and synthesis 
as well as to determine the expression profile of genes involved in cysteine metabolism; 3) To 
evaluate the modulation of cell features such as migration, cell viability and cell cycle by cysteine 
in cells grown in glutamine, and 4) To determine the relevance of glutamine and cysteine 
metabolism in GSH synthesis.   
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3. Materials and Methods 
 
3.1 Role of glucose, glutamine, lactate and butyrate as gluconeogenic precursor and 
cysteine associated with glutaminolysis  
 
3.1.1 Cell culture 
ES2 cell line, an in vitro model of OCCC, was obtained from American Type Culture 
Collection (ATCC) (CRL-1978™). 
Cells were maintained at 37°C in a humidified 5% CO2 environment in Dulbecco’s modified 
essential medium 1X (DMEM) (41965-039, Gibco) containing 4.5g/L of D-glucose and L-
glutamine 0.58 g/L. Medium was supplemented with 10% fetal bovine serum (FBS) (S 0615, 
Biochrom) and 1% Antibiotic-Antimycotic (AA) (15240062, Anti-Anti, Invitrogen).  
Cells were grown to 75%-100% optical confluence before they were detached by 
incubation with 1X 0.05% trypsin- Ethylenediamine tetraacetic acid (EDTA) (25300-054, 
Invitrogen) at room temperature (RT) for 5 min. Whenever necessary, the cell number was 
determined with the help of a Bürker counting chamber. 
In gluconeogenic assays cells were conditioned to DMEM without D-glucose/ L-glutamine 
(F 0405, Biochrom) supplemented with 1% FBS (S 0615, Biochrom), 1% AA (15240062, Anti-
Anti, Invitrogen) and exposed either to 5mM glucose (G8270, Sigma), 50% lactate 
(1.06522.2500, Merck) at 10 mM, to 8 mM glutamine (25030-081, Gibco) or 8mM butyrate (B10 
350-0, Sigma-Aldrich). Cells grown in control conditions were maintained in the absence of 
glucose, lactate, glutamine and butyrate. In cysteine assays, ES2 were also exposed to DMEM 
without glucose (11966-025, Gibco) supplemented with 1% FBS (S 0615, Biochrom), 1% 
Antibiotic-Antimycotic (15240062, Anti-Anti, Invitrogen) and 0.420 mM cysteine. Cells grown in 
control conditions were maintained in the absence of cysteine. In NMR assays cells were 
exposed to DMEM without D-glucose/ L-glutamine (F 0405, Biochrom) supplemented with 1% 
FBS (S 0615, Biochrom), 1% AA (15240062, Anti-Anti, Invitrogen) and 8mM 13C-[U]-glutamine 
(605166, Sigma), 8mM sodium 13C-[U]-butyrate (Isotec) or 10mM sodium 13C-[U]-lactate (Sigma-
Aldrich®).  
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3.1.2 Nuclear magnetic resonance (NMR) for metabolomic detection 
 Nuclear magnetic resonance (NMR) spectroscopy combined with advanced multivariate 
analyses methodologies have several advantages over classical biochemical assays. Essentially 
it represents a powerful, reproducible, and inexpensive technique for investigating the 
metabolome without extensive sample preparation that can be combined with 13C-labeled 
substrates, alloing a noninvasive measurement of metabolic fluxes (Bodi et al., 2012).  
 In the context of the present thesis NMR assay was performed to identify the glutamine, 
lactate and butyrate metabolism in ES2 cell line and their possible influence as gluconeogenesis 
precursor.  
 ES2 cell line were plated 75 cm2 tissue culture flasks (T75) and maintenance in DMEM 
(41965-039, Gibco) supplemented with 10% FBS (S 0615, Biochrom) and 1% AA (15240062, 
Anti-Anti, Invitrogen) until expected 60% optical confluence (~5.5x106 cells/mL) in incubation at 
37ºC and 5% CO2. Confluent cells were placed in starvation (DMEM without FBS) ON at 37ºC 
and 5% CO2 (to synchronize cells). After that, cells were treated with 8mM 13C-[U]-glutamine 
(605166, Sigma), 8mM sodium 13C-[U]-butyrate (Isotec), and 10mM sodium 13C-[U]-lactate 
(Sigma-Aldrich®), in DMEM without D-glucose/ L-glutamine (F 0405, Biochrom) supplemented 
with 1% FBS (S 0615, Biochrom), 1% AA (15240062, Anti-Anti, Invitrogen), for 16 and 48 hours. 
The supernatants were collected and stored at - 80ºC whereas cells were washed twice in PBS 
1x, scraped and centrifuged at 1200 rpm for 2 min. Methanol and chloroform extraction was 
performed in cell pellets for detach organic and aqueous phases. Cell pellets were weighed to 
calculate the methanol volume added for sample (4ml methanol/1g weight pellet). After cold 
methanol mixture, the water was added (double volume of methanol), mixed and incubated for 5 
min on ice. Chloroform (same volume methanol) was added to the sample and mixed. Then, 
water (same volume methanol) was added and samples were incubated for 10 min on ice, 
following centrifugation at 4000 rpm for 15min at 4ºC. Organic and aqueous phase was 
performed with glass pipette and stored at -20ºC until lyophilization. Lyophilization of the aqueous 
phase was made using Speed Vac Plus Scllon and then dissolved in deuterated water (D2O) and 
4% (v/v) azide (N3) / 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS) solution (1:10). To 
supernatants was also added 50µl of D2O and 4% (v/v) N3 / DSS solution. NOESY 1DPR 1D 
(1H), HSQC 2D (1H, 13C) and TOCSY 2D (1H, 1H) spectrums were obtained in a magnetic field of 
800 MHz at 25ºC in UltrashiedTM 800 Plus (Bruker) with TXI probe and COSY 2D (13C, 13C) 
spectrum was obtained in a magnetic field of 500 MHz at 25ºC in UltrashiedTM 500 Plus (Bruker) 
with 13C Dual probe. Software used in acquisition was Topspin 2.1 on avance 800 (Bruker) and 
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spectrums analysis were done according the chemical shifts supported with the Human 
Metabolome database (HMDB) (http://www.hmdb.ca/) and Chemomx NMR suite 7.6.  
 
 
3.1.3 Gene expression 
In the present thesis, gene expression of gluconeogenic enzymes (PCK1, PCK2, FBP1 
and PFKFB1) was determined to study the possible role of glucose, glutamine, lactate and 
butyrate as gluconeogenic precursors. The possible association between cysteine degradation 
and glutaminolysis was also evaluated (culture conditions are specified in 3.1.1).  
 
3.1.3.1 Reverse transcription polymerase chain reaction (RT-PCR) 
Reverse transcription polymerase chain reaction (RT-PCR) is one of the variant in 
polymerase chain reaction (PCR), used mainly for quantifying mRNA in biological samples. This 
technique produces a single-stranded complementary DNA copy (cDNA) of an RNA template 
through the action of the enzyme reverse transcriptase. Following RT reaction, cDNA is amplified 
by PCR (Freeman et al., 1999).  
Ribonucleic acid (RNA) from biological samples was extracted using RNeasy Mini 
Extraction kit (74104, Qiagen) according to the manufacturer’s protocol. RNA concentration was 
determined by measuring the absorbance at 260 nm in a Nanodrop 2000 (Thermo Scientific).  
cDNA was synthesized from 1µg RNA, which was reversely-transcribed by SuperScript II 
Reverse Transcriptase (18080-44, Invitrogen). Firstly, to complete a final volume of 8µl, 0.5µl of 
random hexamers (11034731001, Roche) and bidestilled water (ddH2O) were added to 1µg 
RNA. The reaction mixture was incubated at 70ºC for 10 min, in order to occur the annealing 
between RNA and primers. Then the reaction mixture was refreshed until 4ºC in order to add the 
following mixture: 4 μl first Strand Buffer 5X (Y00146, Invitrogen), 2 μl dithiothreitol 0.1M  (DTT) 
(Y00147, Invitrogen), 2 μl deoxynucleotides (dNTPs) mix (10mM) (28-4065-22V, 28-4065-02V, 
28-4065-12V and 28-4065-32V, GE Healthcare), 1 μl RNAse OUT™ Recombinant RNase 
Inhibitor 40 U/μl (10777-019, Invitrogen), 1 μl Superscript II® 200 U/μl (18064-022, Invitrogen) 
and ddH2O to complete a total volume 12µl.  cDNA synthesis was performed in a T3000 
thermocycler (Biometra), using the following conditions (Table 1).  
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Table 1- Program used for cDNA synthesis 
Stage Cycles Temperature (ºC) Time (min) 
Denaturation 1 70 10 
Cooling 1 4 3 
cDNA synthesis 1 42 90 
Inactivation 1 75 15 
Cooling  4 ∞ 
  
 
3.1.3.2 Relative quantifying PCR (RQ-PCR) 
Relative Quantifying PCR (RQ-PCR) consists in gene expression analysis with accuracy, 
sensitive and fast results, allowing the absolute or relative quantification of messenger ribonucleic 
acid (mRNA transcription) (Derveaux et al., 2010). RQ-PCR analysis is normalized for an 
endogenous control also known as housekeeping gene (gene expressed constitutively) (Gubern 
et al., 2009).  
For RQ-PCR a reaction mixture was performed for all genes of interest for each sample. 
A reaction mixture was made in triplicate, for a total volume of 7 μl per reaction, containing 1μl 
cDNA, 3.5 μL LightCycler 480 SYBR Green I master (04707516001, Roche), 2 μL LightCycler 
480 SYBR Green II master H2O (04707516001, Roche) and 0.5 μL of both forwad and reverse 
primers (5 μM), according to the program described in table 2, using  LightCycler 480 instrument 
(Roche). In all assays, the housekeeping gene used to normalize the samples was Hypoxanthine 
phosphoribosyltransferase (HRPT) gene.  
 
 
Table 2- Relative quantifying PCR program 
Stage Cycles Temperature (ºC) Time 
Heat activation 1 95 10 min 15 sec 
PCR 
Denaturation 
  
95 
 
15 sec 
Annealing 45 60 15 sec 
Elongation  72 20 sec 
Melting 1 60 
95 
14 sec 
14 sec 
Cooling  40 10 sec 
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3.1.4 Protein levels 
 Cells were exposed to glucose, glutamine, lactate and butyrate to understand the role of 
these compounds as precursors of gluconeogenesis in ES2. The levels of gluconeogenic proteins 
(PCK1, PCK2, FBP1 and PFKFB1) were evaluated by western blot for all experimental conditions 
(culture conditions specified in 3.1.1).  
 
3.1.4.1 Western Blotting  
Western blotting is one of the gold standard protein analytical techniques. This assay 
allows target proteins to be specifically detected in complex biological samples, by interaction 
with antibodies after separating the proteins by SDS-PAGE and transferring them to a membrane 
(Liu et al., 2011). 
Cell pellets were lysed in Radio-Immunoprecipitation Assay (RIPA) buffer (Appendix A) 
and stored at -20ºC, ON. The lysates were centrifuged at 14000 rpm for 4 min at 4ºC. 
Supernatants were used, in part, for determination of protein concentration, based on Bradford 
method, using Bio-Rad protein assay reagent (500-0006, Bio-Rad) through spectotrophometric 
quantification (595 nm). Following quantification, Loading buffer 5x (Appendix A) with 10% β-
mercaptoethanol (M3148, Sigma) was added to each lysate and boiled at 95-100ºC for 10 min, to 
denature proteins. After that, samples were centrifuged at 14000 rpm for 2 min at 4ºC and then 
placed in ice.  
The same amount of total protein from each sample was loaded in 15% polyacrylamide gel 
(Tris-glycine SDS-Polyacrylamide gel) (Appendix A) and electrophoresis was carried out in MINI-
PROTEAN Tetra Electrophoresis System (Bio-Rad) at 150V for 1h30, into 1X TGS buffer (Tris-
Glycine-SDS 10x (TGS), 161-0772, Bio-Rad) and then transferred to a Immun-Blot® PVDF 
membrane with a Mini Trans-Blot® Electrophoretic Transfer Cell (Bio-Rad), at 60V and at 4ºC, 
overnight (ON).  Non-specific bindings to the membrane were blocked using 5% (weight 
(w)/volume(v)) non-fat milk in phosphate buffered saline 1x (PBS) 0.1% (v/v) Tween 20 (Appendix 
A) for 2 h at room temperature (RT), with gentle shaking. For protein detection, membranes were 
incubated with primary specific antibodies (Anti-PCK1, R04368, Sigma; Anti-FBP1, R07412, 
Sigma; Anti-PFKFB1, SAB1408617, Sigma), at appropriate concentrations (1:250 in 5% (w/v) 
non-fat milk in PBS 0.1% (v/v) Tween 20 (Appendix A)) at 4ºC, ON, with shaking.  
The membrane was rinsed 3 times, for 5 min, with PBS 1x 0.1% (v/v) Tween 20, to remove 
unbound primary antibody. Membranes were then incubated for 2 h at RT with secondary 
antibody IgG-conjugated Horse raddish peroxidase (HRP) (anti-rabbit (31460, Thermo Scientific)) 
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in appropriate concentrations (1:5000 in 5% (w/v) skin milk in PBS 0.1% (v/v) Tween 20 
(Appendix A)). After rinsing the membrane 3 x 5 min with PBS 1x 0.1% (v/v) Tween 20, 
immunoreactive bands were detected by using ECL western blotting substrate (SuperSignal® 
West Pico Chemiluminescent Substrate (34080, Thermo Scientific) in a ChemiDoc XRS System 
(Bio-Rad) with Image Lab software. To normalize the protein levels in samples, membranes were 
rinsed 3 times, for 5 min, with PBS 1x 0.1% (v/v) Tween 20 and reprobed using anti β-actin 
(A5441, Sigma) at 1:1000 in 5% (w/v) skin milk in PBS1x  0.1% (v/v) Tween 20 (Appendix A), at 
4ºC, ON, and then revealed as describe above. Bands were analyzed and quantified using Image 
J software (rsb.info.nih.gov/ij/).  
 
3.1.5 Promoter activity using Luciferase reporter gene assay  
Promoters are important regulatory elements that contain the necessary sequence 
features for cells to initiate transcription. Transient transfection promoter activity assay using a 
luciferase reporter gene is considered as a direct method for characterizing functional promoter 
sequences, providing a rapid, sensitive, and quantitative basis in the analysis of factors that 
potentially regulate mammalian gene expression in vitro. This technique, based on plasmid 
constructs, is characterized by the fusion of a reporter gene, such as firefly (Photinus pyralis) 
luciferase with a putative promoter sequence (inserted upstream from the reporter gene), allowing 
the measurement of the transcription activity of the reporter genes, and, thus, the inference about 
the promoter activity of the inserted regulatory fragment (Landolin et al., 2010).   
Bioluminescence permits the high sensitive analysis of transient transfection assay, being 
the luciferase protein concentration proportional to the luminescence output. To minimize errors, 
it is desirable to include a co-transfected internal control with a second reporter gene 
constitutively active, for example Renilla (Renilla reniformis) as an internal control for 
normalization. The sequential measurement of these two luciferases (dual luciferase reporter 
system) from a single sample minimizes experimental variability, such as differences in cell 
viability, transfection efficiency, pipetting errors, cell lysis efficiency, and assay efficiency (Solberg 
and Krauss, 2013).  
 
3.1.5.1 Amplification of promoter sequences 
Genomic DNA (gDNA) was extracted using DNA Purification Protocol for 1-2 Million Cells 
(Citogene) from HCT15 cells, according to manufacturer’s protocol. Starting from this DNA, PCR 
amplification was performed, using specific primers (with and without restriction) (Table 8) to flank 
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the sequences of interest (PCK1, PCK2, FBP1, PFKFB1, CTH and MPST promoter sites). PCR 
reaction mixture had 0.1 µg DNA, 2.5 µl PCR Rxn Buffer 10x (-MgCl2) (Y02028, Invitrogen), 2µl 
dNTPs (28-4065-22V, 28-4065-02V, 28-4065-12V and 28-4065-32V, GE Healthcare), 1.5 µl 50 
mM magnesium chloride (MgCl2) (P/N Y02016, Invitrogen), 0.1 µl 5 U/µl Taq DNA Polymerase 
(18038-026, Invitrogen), 1 µl reverse and forward primer (10 µM) and sterile ddH2O to complete 
a total volume of 25 µl, in a T3000 thermocycler (Biometra) as described in table 3.  
 
Table 3- PCR program used for amplification of promoters sequences 
State Cycles Temperature (ºC) Time 
Initial denaturation 1 95 5 min 
Denaturation  
10 
94 50 sec 
Annealing Tann1 30 sec 
Elongation 72 50 min 
Denaturation 25 94 50 sec 
Annealing Tann2 30 sec 
Elongation 72 50 min 
Final elongation 1 72 7 min 
Cooling  15 ∞ 
 
1Annealing temperature (Tann) of primers without restriction sites: PCK1 Forward(For)Reverse(Rev) 59.6ºC; PCK2 ForRev 59.9 
ºC; FBP1 ForRev 61.4ºC; PFKFB1 60.1ºC; CTH ForRev 60.6 ºC; MPST ForRev 60.4 ºC  
2Tann of primers with restriction sites: PCK1 ForRev 66.8ºC; PCK2 ForRev 68.1 ºC; FBP1 ForRev 68.9ºC; PFKFB1 68.1ºC CTH 
ForRev 67.5 ºC; MPST ForRev 67.4 ºC 
 
 The annealing temperature (Tann) of the primers was determined using the following 
equation:    
 
 
 
The amplified PCR products were analyzed by electrophoresis, on a 2% (w/v) SEA KEM 
® GTG ® agarose (50074, FMC BioProducts) gel (in TBE buffer 1x, diluted from TBE buffer 10 x, 
EC-860, National diagnostics) labelled with 0.05% (v/v) ethidium bromide 10 mg/ml (15585-011, 
Invitrogen), under UV (BioDocAnalyse Transilluminator, Biometra).  DNA fragments with 
expected size were extracted from agarose gel and purified resorting to IllustraTM GFXTM PCR 
DNA and Gel Band Purification kit (28-9034-71, GE Healthcare), according to the manufacturer’s 
protocol. After purifying, the DNA fragments were sequenced by automated sequencing.   
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3.1.5.2 DNA automate sequencing of promoter sequences 
DNA automated sequencing was used to confirm the nucleotide sequences of the PCR 
products. Sequencing reaction mixture contained 3 μL of Big dye™ Terminator v1.1, 2 μL of  Big 
dye sequencing buffer 5x (BigDye® Terminator v3.1 Cycle Sequencing kit, 4337456, Applied 
Biosystems), 1 μL of forward or reverse primer (at 3.33 μM) (Table 8), about 100 ng of template 
DNA and ddH2O up to 20 μL. Sequencing reaction was carried out in a T3000 thermocycler 
(Biometra), according to the program described in table 4. Sequencing reaction mixture was 
purified with AutoSeq G-50 dye terminator removal kit (27-5340-02, GE Healthcare Life 
Sciences), according to manufacturer’s instructions and then evaluated in an ABI Prism™ 310 
Genetic Analyzer (Applied Biosystems).  
 
Table 4- Automate sequencing program 
Stage Cycles Temperature (ºC) Time 
Initial denaturation 1 96 5 min 
Denaturation  96 10 sec 
Annealing 30 Tann1 5 sec 
Elongation  72 4 min 
Cooling  4 ∞ 
 
1Tann of primers without restriction sites: PCK1 For 59.4 ºC; PCK1 Rev 59.8 ºC; PCK2 For 60.3 ºC; PCK2 Rev 59.4 ºC; FBP1 For 
60.9 ºC, FBP1 Rev 59.4 ºC; PFKFB1 For 60.3 ºC; PFKFB1 Rev 59.8 ºC; CTH For 61.4 ºC; CTH Rev 59.8 ºC; MPST For 61.4 ºC; 
MPST Rev 59.4 ºC. When temperature was higher than 60ºC, the temperature used was 59.5ºC.  
 
 
3.1.5.3 Plasmid generation and cloning  
In the present experimental work, luciferase plasmid pGL3-Basic (Figure 8 a) was used 
as a negative control and pGL3-Control (Figure 8 b) as a positive control. pGL3-Basic vector 
lacks eukaryotic promoter and enhancer sequences, allowing maximum flexibility in cloning 
putative regulatory sequences. Expression of luciferase activity in cells transfected with this 
plasmid depends on the insertion and proper orientation of a functional promoter upstream from 
luc+; the vector contains a modified coding region for firefly (Photinus pyralis) luciferase, 
optimized for monitoring transcriptional activity in transfected eukaryotic cells. pGL3-Control 
vector contains SV40 promoter and enhancer sequences, resulting in strong expression of luc+ in 
many types of mammalian cells. This plasmid is useful in monitoring transfection efficiency, in 
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general, as it is a convenient internal standard for promoter and enhancer activities expressed by 
pGL3 recombinants (Technical Manual - pGL3 Luciferase Reporter Vectors, Promega). 
 
 
Figure 8: a) pGL3-Basic Vector. b) pGL3-Control Vector. Adapted from Technical Manual - pGL3 Luciferase 
 
Amplified promoter sequences (PCK1, PCK2, FBP1, PFKFB1, CTH and MPST) (Table 8) 
and pGL3 basic vector (Figure 8 a) were digested with BglII 40 U/ µl (1175068, Boehringer 
Mannheim GmbH), HindIII 10 U/ µl (#ER0505, Fermentas) or MluI 10 U/ µl (#ER0561, 
Fermentas) restriction enzymes, depending on the fragment. The digestion reaction was 
performed at 37ºC, ON, in a T3000 thermocycler (Biometra) and then purified with IllustraTM 
GFXTM PCR DNA and Gel Band Purification kit (28-9034-71, GE Healthcare), according to the 
manufacturer’s protocol. The digested fragments were then inserted into PGL3 basic vector, also 
digested, through the ligation reaction containing 1.8 μL 10x T4 DNA ligase buffer (B69, 
Fermentas), 1μL T4 DNA ligase (EL0011, Fermentas), 0.2 μL pGL3 basic vector, 15 μL of 
digested DNA and ddH2O to complete a total volume of 20 µl, in a T3000 thermocycler 
(Biometra), ON, at 16ºC.  
 After ligation reaction, recombinant plasmids were cloned into One-shot TOP 10 
Chemically Competent Escherichia coli (C4040-10, Invitrogen), according to the manufacturer’s 
instructions.  
 
3.1.5.4 Plasmid isolation  
Positive colonies were selected by ampicillin resistance (Figure 8 a) and from each plate, 
10 colonies were cultured in 5 ml of Luria-Bertani medium (LB) medium (with 50 μg/ml ampicillin) 
(Appendix A), at 37ºC, ON, with shaking. The isolation of recombinant plasmids from each culture 
were purified using Plasmid DNA MiniPreps kit (SP-PMN-100, EasySpin, Citomed), according to 
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the manufacturer’s protocol. Following isolation, plasmid DNA concentration was obtained 
spectrophotometrically in a Nanodrop 2000 (Thermo Scientific). Recombinant plasmids were 
digested once again with the restriction enzymes previously used, with the purpose of confirm the 
insertion of the fragments of interest. After electrophoresis, the digestion products were visualized 
on a 2% (w/v) SEA KEM ® GTG ® agarose (50074, FMC BioProducts) gel (in TBE buffer 1x, 
diluted from TBE buffer 10x, EC-860, National diagnostics) stained with 0.05% (v/v) ethidium 
bromide 10 mg/ml (15585-011, Invitrogen), under UV (BioDocAnalyse Transilluminator, 
Biometra). In positive colonies for fragments of interest, PCR amplification was performed with 
RVprimer3 and GLprimer2 (pGL3 sequencing primers – table 8) (Table 5). 
 
Table 5- PCR program for plasmid constructs amplification 
Stage Cycles Temperature (ºC) Time 
Initial denaturation 1 94 5 min 
Denaturation  94 50 sec 
Annealing 35 56,9 30 sec 
Elongation  72 1 min 
Final elongation 1 72 7 min 
Cooling  4 ∞ 
 
 Automated sequencing was used to confirm the exact position and the nucleotide 
sequence of the DNA inserted into pGL3 vector. The sequencing reaction mixture was performed 
using 10 ng of plamid DNA, 1 μL sequencing primers (at 3.33 µM) (Table 6), 4 µl of Big dye™ 
Terminator v1.1, 2 μL of 5X Big dye sequencing buffer (BigDye® Terminator v3.1 Cycle 
Sequencing kit, 4337456, Applied Biosystems) and ddH2O to complete a total volume of 25 µl, in 
a T3000 thermocycler (Biometra) as described in table 6. Sequencing reaction products were 
purified using AutoSeq G-50 GFX (27-5340-03, GE Healthcare) accordingly to manufacturer’s 
protocol, and then analyzed in a ABI Prism 3130 Genetic Analyzer. 
 
Table 6- Automate sequencing program 
Stage Cycles Temperature (ºC) Time 
Initial denaturation 1 96 5 min 
Denaturation  96 10 sec 
Annealing 30 56,9 5 sec 
Elongation  60 4 min 
Cooling  4 ∞ 
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To amplify the selected plasmid DNA, in which the fragment was inserted properly, a 
second transformation of One-shot TOP 10 Chemically Competent Escherichia coli (C4040-10, 
Invitrogen) was performed, according to the manufacturer’s protocol. The colonies were cultured 
in 30 ml LB medium (with 50 μg/ml ampicillin) and purified using Plasmid DNA Midipreps Kit 
(12143, Qiagen) according to manufacturer’s protocol.DNA concentration was then determined 
spectrophotometrically in a Nanodrop 2000 (Thermo Scientific). 
 
 
3.1.5.5 Transient transfection of promoters constructs into ES2 cell line  
Before transfection, ES2 cells were trypsinized with 1x 0.05% trypsin-EDTA (25300-054, 
Invitrogen) and plated at 2.5x105 cells/mL in 24-well plates, with DMEM supplemented with 10% 
FBS and 1% AA. For transfection, per well, 3 µl of Lipofectamine 2000 (11668, Invitrogen), 0.5 
µg of each plasmid construct  (PCK1, PCK2, FBP1, PFKFB1, CTH and MPST) and 0.1 µg 
Renilla plasmid (1:5 ratio) were used in DMEM, at 3:1 ratio. pGL3-Control Vector (Figure 8 b) was 
used as positive control and pGL3-Basic Vector (Figure 8 a) as negative control, at the same 
concentration used for plasmid constructs. Plasmids and liposomes into DMEM were incubated 
separately for 5 min, at RT, and then mixed and incubated for another 20 min. One hundred µl of 
transfection complex were added to each well. Cells exposed to transfection complex were kept 
at 37ºC for 4-6h. After that time, 500 µl DMEM (41965-039, Gibco) supplemented with 10% FBS 
(S 0615, Biochrom) and 1% AA (15240062, Anti-Anti, Invitrogen) were added to each well, 
followed by incubation ON at 37ºC and 5% CO2. For PCK1, PCK2, FBP1 and PFKFB1 
constructs, 24h after transfection cells were exposed to DMEM without D-glucose/ L-glutamine (F 
0405, Biochrom) supplemented with 1% FBS, 1% AA and 5 mM D-glucose (G8270, Sigma), 8 
mM L-Glutamine (25030-081, Gibco), 10 mM NaLac (1.06522.2500, Merck), 8 mM Butyric acid 
(B10 350-0, Sigma-Aldrich) for PCK1, PCK2, FBP1 and PFKFB1 plasmid constructs. For CTH 
and MPST constructs, cells were exposed to DMEM without glucose (11966-025, Gibco) 
supplemented with 1% FBS, 1% AA and 0.402 mM cysteine. Cells transfected in control 
conditions were maintained in DMEM without glucose (11966-025, Gibco) supplemented with 1% 
FBS, 1% AA. Cells were harvested 48h post-transfection and lysed with Passive lysis buffer 1x  
(Passive lysis buffer 5x, E194A, Promega) and frozen at - 80ºC, ON. The experiments were 
performed in triplicates. 
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3.1.5.6 Luciferase activity  
To evaluate the luciferase activity of constructs, Firefly and Renilla luciferase activities 
were measured sequentially from a single cell lysate in a Victor3 1420 Multilabel Counter 
Luminoter (Perkin Elmer), using the Dual Luciferase Assay System (E1910, Promega) according 
to the manufacturer’s protocol. The experiments were made in triplicates and the results were 
normalized to the pGL3-Basic vector activity, as a ratio of firefly luciferase activity to Renilla 
luciferase activity.  
 
 
3.2. Role of glucose, glutamime, lactate, butyrate and cysteine in cell migration, cell 
cycle and apoptosis regulation  
 
3.2.1 Cell migration - In vitro wound healing assay  
 In vitro wound healing assay is an easy, low-cost and well-developed method to measure 
cell migration in vitro. The basic steps involve an “injury” by ‘‘scratching’’ a cell monolayer, 
Images must be captured at the beginning and at regular timepoints during cell migration until the 
scratch closure, and then compared to quantify cell migration rates. This method permits the 
study of directional cell migration in vitro that mimics the migration of cells during wound healing 
in vivo (Liang et al., 2007). In the present experimental work, this assay was performed to identify 
a possible role of glucose, glutamine, lactate, butyrate and glutamine plus cysteine on cell 
migration, by comparison to control conditions (culture conditions specified in 3.1.1).  
 ES2 were plated in twelve-well culture plates at a 2.5 x 105 cells/mL concentration and 
maintained in DMEM (41965-039, Gibco) supplemented with 10% FBS (S 0615, Biochrom) and 
1% AA (15240062, Anti-Anti, Invitrogen) until a confluent monolayer. In order to inhibit cell 
proliferation that could mask migration results, when cells were in expected optical confluence, 
they were treated with 5 µg/mL Mitomycin-C (M4287, Sigma), an antiproliferative agent, for 3 h at 
37ºC, 5% CO2. After that, in each well a tip of micropipette (P200 tip) was used to make a linear 
scratch along the well biggest diameter, creating a wound in the cell layer. The culture medium 
was replaced after the scratch in order to remove detached cells and to expose cells to the 
different experimental conditions, as described above. Cell were photographed under an 
Olympus CK2 inverted optical microscope (Olympus) at the following time points: 0, 8, 24, 36 and 
48 h. Photographs were analyzed with Image J software (rsb.info.nih.gov/ij/) to estimate wound 
closure in the different experimental conditions. 
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3.2.2 Cell cycle analysis by Flow Cytometry  
 Loss of control of cell proliferation underlies the pathology of diseases like cancer. As 
such there is a great need to investigate cell proliferation and cell cycle activity (Cecchini et al., 
2012). Cell division consists of two consecutive processes, mainly characterized by DNA 
replication and segregation of replicated chromosomes into two separate cells. Replication of 
DNA occurs in a specific part of the interphase called S phase. S phase is preceded by a gap 
called G1 during which the cell is preparing DNA synthesis and is followed by a gap called G2 
during which the cell prepares for division. G1, S, G2 and M phases are the traditional 
subdivisions of the standard cell cycle (Vermeulen et al., 2003).  
DNA content in cells can be readily quantitated by flow cytometry of cells stained with 
propidium iodide (PI) - a fluorescent DNA intercalating dye – which binds to DNA in cells fixed 
with ethanol. In flow cytometry four distinct phases could be recognized in a proliferating cell 
population: G1, S, G2 and M, however G2 and M cannot be distinguished (Cecchini et al., 2012).  
 In the present experimental work, this assay was performed to identify a possible role of 
glucose, glutamine, lactate, butyrate and glutamine plus cysteine (culture conditions specified in 
3.1.1) in the regulation of cell cycle. 
 ES2 cell lines were plated in six-well plate tissue dishes at a 2.5 x105 cells/ mL 
concentration, and maintained in DMEM (41965-039, Gibco) supplemented with 10% FBS (S 
0615, Biochrom) and 1% AA (15240062, Anti-Anti, Invitrogen). When cells were adherent (~8 h 
later) they were kept under starvation (DMEM without FBS) (to synchronize cells). After that, at  
time point  0h some cells were harvested (control) and others were stimulated with the different 
media, as described above (culture conditions specified in 3.1.1). Cells were collected at 6, 24, 30 
, 48 and 60 h after stimulation, and fixed in 70% ethanol (100983, Merck) at 4ºC. Cells were 
centrifuged at 1500 rpm for 5 min and then stained with 100 µl 50 µg/mL PI solution (Appendix 
A) and incubated at 37ºC for 40 min. 1X PBS  was added after incubation and the cells were 
centrifuged at 1500 rpm for 5 min at 4ºC. The supernatant was discarded and cells were 
resuspended in 200 µl PBS 1x 0.1% (w/v) bovine serum albumin (BSA) (Appendix A) and 
analyzed by flow cytometry (FACScalibur – Becton Dickinson). The experiments were made in 
triplicates. In flow cytometric analysis death cells and cell aggregates were excluded.  
 
3.2.3 Apoptosis analysis by Flow Cytometry  
 Apoptosis is distinguished from necrosis, or accidental cell death, by characteristic 
morphological and biochemical changes, including compaction and fragmentation of the nuclear 
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chromatin, shrinkage of the cytoplasm, and loss of membrane asymmetry. In normal live cells, 
phosphatidyl serine (PS) is located on the cytoplasmic surface of the cell membrane. However, in 
apoptotic cells, PS is translocated from the inner to the outer leaflet of the plasma membrane, 
thus exposing PS to the external cellular environment. Labeled Annexin V allows the identification 
of apoptotic cells by binding to PS exposed on the outer leaflet, and PI, which is impermeant to 
live and apoptotic cells, stains dead cells binding tightly to the nucleic acids in the cell (Technical 
Manual - Alexa Fluor® 488 annexin V/Dead Cell Apoptosis Kit with Alexa® Fluor 488 annexin V 
and PI for Flow Cytometry, Invitrogen). 
 In the context of the present thesis apoptosis assay was performed to identify a potential 
role of glutamine and glutamine plus cysteine in the regulation of apoptosis in ES2 cell line.  
 ES2 cells were plated in twelve-well plate tissue dishes at a 2.5 x105 cells/ mL 
concentration and maintained in DMEM supplemented with 10% FBS and 1% AA. After adhering 
(~8 h later) cells were kept under starvation (DMEM without FBS) ON at 37ºC and 5% CO2. After 
that, at time point 0 h some cells were harvested (control) and others were stimulated with 
glutamine and glutamine plus cysteine (culture conditions specified in 3.1.1). Cells exposed to the 
different experimental conditions were collected at 6, 24, 30, 48 and 60 h, by harvesting with 100 
µl of 1X 0.05% trypsin-EDTA (25300-054, Invitrogen) per well. Cells were centrifuged at 1200 
rpm for 2 min and stained with 1.25 µl Alexa Fluor® 488 annexin V and 1.25 µl PI solution 
(50µg/mL) and incubated at RT and in dark for 15 min. After incubation, samples were 
resuspended in 200 µl PBS 1x 0.1% (w/v) BSA (Appendix A) twice and centrifuged at 1200 rpm 
for 2 min. The supernatant was removed and cells were resuspended in 100 µl of annexin V 
binding buffer 1X (Appendix A) and analyzed by flow cytometry (FACScalibur – Becton 
Dickinson). The experiments were made in duplicates.  
 
 
3.3 Role of cysteine in aminothiols production  
 
3.3.1 High-performance Liquid Chromatography (HPLC) for aminothiols detection  
Thiols are chemically and biochemically very active components and low molecular-
mass thiols, such as homocysteine (HCY), cysteine (CYS), cysteinylglycine (CysGly) and 
glutathione (GSH) are critical cellular components that play numerous roles in metabolism, cell 
signaling, detoxification and homeostasis, being important in a variety of physiological and 
pathological processes (Nolin et al., 2007). Intracellular thiols such as GSH are essential in 
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maintaining the highly reduced environment inside the cell, while extracellular thiols such as CYS 
also constitute an important component in antioxidant defense (Kuśmierek et al., 2009).  
HPLC with ﬂuorescence detection (HPLC–FD) is the most commonly used method for 
determination of aminothiols due to its high sensitivity, relative simplicity, ease of automation, and 
high throughput capability. Sample preparation usually involves disulﬁde reduction, protein 
precipitation, and derivatization prior to chromatographic separation (McMenamin et al., 2009). 
In the present thesis this assay was performed to understand the possible role of L-
cysteine addiction comparatively to the control (only glutamine presence) in aminothiols 
production, namely in the influence in endogenous antioxidant GSH pathway.  
 ES2 cells were plated in 75 cm2 tissue culture flasks (T75) and maintained in DMEM 
(41965-039, Gibco) supplemented with 10% FBS (S 0615, Biochrom) and 1% AA (15240062, 
Anti-Anti, Invitrogen) until expected 70% optical confluence (~6.4x106 cells/mL). Confluent cells 
were exposed to DMEM without glucose (11966-025, Gibco) supplemented with 10% FBS (S 
0615, Biochrom) and 1% AA (15240062, Anti-Anti, Invitrogen) and 0.402 mM cysteine (culture 
conditions specified in 3.1.1), for 16 h. The supernatants were collected and cells were harvested 
with 1X 0.05% trypsin-EDTA (25300-054, Invitrogen), centrifuged at 1200 rpm for 2 min, rinsed 
twice in 1X PBS (Appendix A) and frozen at -80ºC.  
 In order to perform cell lysis, pellets were resuspended in 250 µl 1X PBS - 0.01% (v/v) 
Triton x-100 and centrifuged at 10000 rpm for 2 min. After that, cell supernatants were filtered in 
Amicon Ultra-15 Centrifugal Filter Units (Merck Millipore) by centrifugation at 3800 rpm for 20 min 
at 4ºC. Cells, cell supernatants and crude culture medium were reduced by the addiction of 10 µl 
100g/L Tris (2-carboxyethyl)phosphine (TCEP) per 100 µl of sample and incubated for 30 min at 
RT. After that, 90 µl 100g/L Trichloroacetic acid (TCA) 1mM EDTA were added and samples 
centrifuged at 13000 rpm for 10 min at 4ºC. TCA acid stops the reduction reaction and induces 
protein precipitation. The resultant supernatants were collected and derived due to the addiction 
of 10 µl 1.55M Sodium hydroxide (NaOH), 125 µl 0.125M Sodium tetraborate- 4mM  EDTA 
(Borate tampon) and 50 µl 1g/L Ammonium 7-Fluoro-2,1,3-benzoxadiazole-4-sulfonate (SBD-F). 
The samples were incubated at 60ºC for 1 hour, protected from ligth.  
 After samples processing, aminothiols quantification by HPLC was performed in 
Schimadzu (Kyoto, Japan) system, consisting of a LC 9-A solvent delivery pump, a 7725i injector, 
a RF-10AXL fluorescence detector and a CTO-10AS VP column oven. A LiChrospher 100 RP-18 
(250 x 4 mm; 5 μm) column protected by a LiChrospher 100 RP-18e (4x 4mm; 5 μm) guard-
column, both from Merck (New Jersey, USA), was used, at 29⁰C. The detector was set at 
excitation and emission wavelengths of 385 nm and 515 nm. Data acquisition and processing 
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were performed in Shimadzu Class VP 7.X software. Calibration curves were constructed six 
standard concentrations of the five aminothiols (HCY, CYS, CysGly, GSH and NAC) in PBS 1X 
and, for each curve, the absolute peak-area ratios were calculated and plotted against the 
nominal aminothiol concentration. 
 
 
3.4 Statistical analysis 
 Results were analyzed by student’s t test or 2-way ANOVA to evaluate the statistical 
significance of results, using GraphPad Prism 6 software. Data’s were considered significant 
when p<0.05.  
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Table 7 - Primers used during the experimental work 
Reference/Target Primer (5’-3’) Tm (ºC) Technique 
BglII pPCK1.For ATGAGATCTGGATGGGTCGCATTTAGGAC 66.7 
PCR 
Automate sequencing 
HindIII pPCK1.Rev ATGAAGCTTCTTCCATGGAAGCCTCTCTAC 66.8 
MluI pPCK2.For TGAGGCGTGATGTGGGGGTGACAACATTAG 69.5 
BglII pPCK2.Rev ATGAGATCTGCTCTGTGTCAGCAACTCTG 66.7 
MluI pFBP1.For ATGACGCGTCTCCCCTCCACATTCCGTG 71 
HindIII pFBP1.Rev ATGAAGCTTGACTCTGCCAGAGAGAAAGC 66.7 
MluI pPFKFB1.For ATGACGCGTCCCTGTAAGGCTAACAAGGATG 69.5 
HindIII pPFKFB1.Rev ATGAAGCTTCCCTCCTTAGGACTGTTGAAG 66.8 
BglII pCTH.For ATGAGATCTCAGCCAATAAGGAGCGGGAG 68.1 
HindIII pCTH.Rer ATGAAGCTTGCTGAACCGCGAAAGAAGAAG 66.8 
BglII pMPST.For ATGAGATCTCGTAGGTCTTGAGCAGGGAG 68.1 
HindIII pMPST.Rev ATGAAGCTTGGAGGGAGAAAGAGCTTCTC 66.7 
RVprimer3 CTAGCAAAATAGGCTGTCCC 57.0 PCR 
Automate sequencing GLprimer2 GGAAGACGCCAAAAACATAAAG 56.0 
PCK1.For GCGGATCATGACGCGGATG 58.8 
RQ-PCR 
PCK1.Rev GAGCGTCAGCTCCGGGTTG 63.1 
PCK2.For CAAGACCAACCTGGCTATGATG 60.3 
PCK2.Rev GAGTCGACCTTCACTGTCAAAC 60.3 
FBP1.For GCTACGCACTGTATGGCAGTG 61.8 
FBP1.Rev CGTAGCCCTCGTTAAGGCTG 61.4 
PFKFB1.For CCAGTATCGACGAGAGGCAG 61.4 
PFKFB1.Rev CTCTGGTAGTGTTGGTGGCATC 62.1 
ALT.For CGTGACGGTGCTGAAGCTG 61.0 
ALT.Rev CTCGTCCAGGTAGTAATCCAC 59.8 
CTH.For GCAGCCACTGTAACTATTACCC 60.3 
CTH.Rev CTGGTGTAATTGCTGCCTCTAG 60.3 
MPST.For CTTCATCAAGACCTACGAGGAC 60.3 
MPST.Rev GGTAGTGGCCAGGTTCAATG 59.4 
mTOR.For CAATGTGAGCGTCCTGCAG 58.8 
mTOR.Rev GACTCCTCTTGACTCATCTCTC 60.3 
 
Tm: melting temperature 
RQ-PCR: Relative quantifying PCR 
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4. Results  
 
4.1 Role of glucose, glutamine, lactate and butyrate as gluconeogenic precursor  
 
4.1.1 Nuclear magnetic resonance (NMR) for metabolic detection in ES2 cell line 
  To evaluate gluconeogenesis in ES2 cell lines, NMR spectroscopy was used. Different 
13C-labeled carbon source were used: 13C-[U]-glutamine, 13C-[U]-lactate and sodium 13C-[U]-
butyrate. 
In ES2 cell extracts no 13C labeled glucose was detected. The profile of 13C-labeled 
compounds varied, depending of the carbon source used (Figure 9).  
It was observed the presence of 13C-labelled glutamine, glutamate, alanine and lactate 
when glutamine was a carbon source. Glycogen was only observed with butyrate as carbon 
source, but it was not 13C-labelled (Figure 9 b).  
 
   
Figure 9- NOESY 1D (1H) spectra for ES2 cell line. Cells were exposed to sodium 13C-[U] –butyrate, sodium 13C-[U] 
–lactate and 13C-[U] –glutamine, ON at 37ºC. Control were cells grown in DMEM without D-glucose/ L-glutamine, 
supplemented with 1% FBS and 1% AA 
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Figure 10: 13C-1H-HSQC spectra of ES2 supernant (A) and cell extracts (B) incubated with 13C-glutamine. 
Cells in starvation were exposed to 13C-[U] –glutamine, for 48 at 37ºC. The 13C labeled compounds identified were: 
Lact- lactate; Pro- proline; Ser- serine; Asp-aspartate; Pyro- pyroglutamate; Aspa- asparagine; Ala- alanine; Gly- 
glycine; Glut- glutamate; Glutm- glutamine. In panel B, it is indicated the resonances of the free glutamate(Glut) 
and glutamate moiety of GSH (GSH-Glut), free glycine (Gly) and glycine moiety of GSH (GSH-Gly), and the N-
acetyl-aspartate (NacAsp). 
 
a)  
b)  
 a)  
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 The glutamine metabolism was further studied in starvation conditions. Cells in starvation 
were incubated 48 hours with 13C-U-glutamine, and further analyzed. 
 As control, it was used cells incubated with unlabelled glucose. In these cases, the 
growth media were also analyzed, in order to evaluate the secreted metabolites.    
 In supernatants of 13C glutamine ES2 cells were detected 13C labeled metabolites, namely 
formate, lactate, alanine, pyroglutamate, aspartate, asparagine, glycine, proline, glutamine and 
glutamate (Figure 10). In the cells, the same 13C labeled metabolites were present besides 
glutathione (GSH) and N-acetlylaspartic acid (Figure 10). The results show that 13C from 
glutamine were incorporated in glycine and glutamate moieties of GSH, but not in the cysteine 
moiety (Figure 11).  
 Organic phase of ES2 cells incubated with 13C glutamine were also analyzed, indicated 
that the glutamine is preferentially used for the synthesis of glycerol backbone of triglycerides and 
phospholipids, and not for the fatty acids synthesis (data not shown). 
 
4.1.2 PCK1, PCK2, FBP1, PFKFB1 and ALT gene expression and protein levels in 
ES2 cell line 
 
The metabolic reprogramming capacity of tumor cells was evaluated in ES2 cells grown in 
glucose and in glucose privation with glutamine, lactate or butyrate, using as control cells grown 
in medium without both glucose and glutamine and supplemented with 1% FBS. The expression 
of gluconeogenic (PCK1, PCK2, FBP1 and ALT) and glycolytic gene (PFKFB1) were assessed by 
Real Time-PCR (Figures 11) and Western Blotting (Figures 12).  
In ES2 it was observed a statistically significant increase in PCK1 expression after glucose 
and butyrate treatment and a decrease after lactate and glutamine (statistically significant) 
treatment, comparing to cells grown in control conditions (Figure 11). The dynamics at mRNA 
levels did not correspond to PCK1 protein levels assessed by Western Blotting (Figure 12 a). 
Comparing to control condition, PCK1 protein profile showed exactly the opposite, lower levels of 
PCK1 with glucose and butyrate treatment and higher in glutamine and lactate conditions (Figure 
11 and 12 a).  
Regarding PCK2 gene expression, after butyrate treatment it was verified an increase in 
mRNA levels while glucose (statistically significant) and lactate treatment induced a decrease in 
mRNA levels, comparing to control condition. Glutamine treatment led to an expression level of 
PCK2 almost equivalent to control condition (Figure 11).  
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The levels of FBP1 protein in ES2 cells was also detected in all conditions although 
glucose, glutamine and lactate exposure led to higher levels of expression. Butyrate exposure 
and control condition showed low levels of FBP1 protein (Figure 12 b).  
A statistically significant increase of mRNA levels of PFKFB1 was observed in glucose, 
butyrate and lactate conditions while in glutamine condition it was verified a decrease in mRNA 
levels of PFKFB1, comparing to cells grown in control condition (Figure 11). Concerning protein 
levels of PFKFB1 assessed by Western Blotting, the dynamics was not the same observed at the 
mRNA levels (Figure 12 c). Lactate condition showed a decrease in PFKFB1 protein levels in 
comparison with control condition while butyrate, glutamine and glucose exposure led to higher 
levels of PFKFB1 protein expression (Figure 12 c).   
 
 
 
 
Figure 11- Relative gene expression of PCK1, PCK2 and PFKFB1. Cells were grown in control, glucose, 
glutamine, lactate and butyrate conditions. HPRT gene was used as endogenous control. Expression levels were 
normalized to control condition. Data are mean ± error bars of triplicates. *p≤0.05 **p ≤0.01 ***p ≤0.001 
****p<0.0001 
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Figure 12– PCK1 (a), FBP1 (b) and PFKFB1 (c) protein levels in ES2cells assessed by western-blotting. Cells 
were grown in control, glucose, glutamine, lactate and butyrate conditions. Protein levels were normalized to β-actin 
and are relative to those obtained for cells grown in control conditions. 
 
 
In the present thesis it was also important to evaluate the expression of alanine 
transaminase (ALT), since it catalyses the conversion of glutamine into alanine, which can be 
canalized to produce glucose, becoming also an important enzyme in gluconeogenesis context.  
It was observed an increase in ALT expression after glucose, lactate, butyrate and 
glutamine treatment, although this increase was statistically significant in glucose and lactate 
conditions (Figure 12). However, when glutamine exposure time was increased from 16 to 30h a 
statistically significant increase in mRNA levels of ALT was observed (Figure 12).   
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Figure 13- Relative gene expression of ALT. Cells were grown in control, glucose, glutamine, lactate and butyrate 
conditions. HPRT gene was used as endogenous control. Expression levels were normalized to those obtained for 
cells grown in control conditions. Data are mean ± error bars of triplicates. *p≤0.05 **p ≤0.01 ****p<0.0001 
 
 
4.1.3 Activity of PCK1, PCK2, FBP1 and PFKFB1 promoters in ES2 cell line 
 
In order to evaluate the influence of different nutrients in the regulation of the expression of 
gluconeogenic and glycolytic genes PCK1, PCK2, FBP1 and PFKFB1, promoters activity was 
evaluated by using Luciferase reporter gene assay  in cells grown in glucose privation medium 
and further stimulated with glucose, glutamine, lactate and butyrate. Different constructs were 
generated using conventional molecular cloning techniques and cells were transfected with 
cationic liposome (Lipofectamine).  
Regarding PCK1 promoter, glucose and butyrate conditions, showed the same level of 
activity verified in control (Figure 14). Higher PCK1 promoter activity was observed in cells 
exposed to lactate, whereas in cells exposed to glutamine a decrease in PCK1 promoter activity 
was observed. Both differences were statistically significant.   
For PCK2 promoter, cells grown in all conditions except glutamine showed higher promoter 
activity comparing to control, being butyrate exposure the condition more favorable to PCK2 
promoter activity (Figure 14).  
FBP1 promoter activity was higher in cells exposed to lactate and glucose, whereas 
butyrate and glutamine exposure induced a decrease in PFKFB1 promoter activity, in relation to 
control all these differences were statistically significant. (Figure 14).  
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Finally, for PFKFB1 promoter only lactate condition induced a statistically significant 
increase in luciferase activity, comparing to control. In glucose, glutamine and butyrate the levels 
were equivalent to control (Figure 14).  
 
 
.  
Figure 14 - Luciferase activity of PCK1, PCK2, FBP1 and PFKFB1 constructs in transfected ES2 cells. Cells 
were grown in control, glucose, glutamine, lactate and butyrate conditions. Data are mean ± error bars of triplicates. 
*p≤0.05 **p ≤0.01 ***p ≤0.001 ****p<0.0001 
 
 
4.2 Role of glucose, glutamine, lactate, butyrate in cell migration and cell cycle in ES2 
cell line 
 
4.2.1 Cell migration - In vitro wound healing assay  
 In vitro wound healing assay was performed to assess a putative role of glucose, 
glutamine, lactate and butyrate on ES2 cells migration. The migration rate was monitorized in 
cells previously submitted to glucose privation at the following time points: 0, 8, 24, 32 and 48 h 
(Figure 15).  
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 During the assay, it was observed a higher cell migration rate (faster wound closure) in 
cells exposed to glucose, glutamine and butyrate, comparing to control (Figure 15 and 16). In 
lactate condition cells showed the same migration rate as the control (Figure 15 and 16).   
 
 
Figure 15- In vitro Wound Healing assay in ES2 cells. Comparison between cells grown in control, glucose, 
glutamine, lactate and butyrate conditions at 0, 8, 24, 32 and 48 h. Phase microscopy (original magnification: 200x). 
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Figure 16- Quantification of wound closure in ES2 cells. Cells were maintained in control, glucose, glutamine, 
lactate and butyrate conditions at 0, 8, 24, 32 and 48 h 
 
 
4.2.2 Cell cycle analysis by Flow Cytometry 
 
Cell cycle analysis was performed to assess the influence of glucose, glutamine, lactate 
and butyrate in cell cycle regulation. Cells were submitted previously to glucose privation.  
The percentage of cells after 6 h in culture (control_6h), showed few alterations in S and 
G2-M phase (44.7% and 15.95%) compared to time point 0 h (S phase 44.7% and G2-M phase 
15.94%) (Figure 17). Butyrate, glutamine and lactate conditions, after 6 h, express an identical 
percentage of cells in S phase (42.57%, 39.41% and 36.79% respectively) and G2-M phase 
(18.03%, 13.02%, 15.35%, respectively) comparing with control (S phase 44.7% and G2-M phase 
15.95%) whereas in glucose condition S phase (42.15%) and G2-M phase (12.47%) was slightly 
lower (Figure 17 b, c and d).  
In time point 24 h, the conditions showing to be more favorable to cell cycle progression 
were butyrate and glutamine (Figure 17 b and d). Under these conditions, S phase (7.72% and 
19.58%) and G2-M phase (32.52% and 7.81%) were higher than control (S phase 5.84% and G2-
M phase 11.35%) (Figure 17 b and d). Identical results were observed in the same conditions 
with 30 h of exposure (Figure 17 b and d).  
Glucose and lactate exposure did not show relevant alterations on cell cycle profile, 
comparing to control condition (Figure 17 a).  
 
 
45 
 
 
Figure 17– Cell cycle analyzes by flow cytometric (PI staining) in ES2 cells. Cells were grown in control, glucose 
(a), glutamine (b), lactate (c) and butyrate (d) conditions at 0, 8, 24, 32 and 48 h. Data are means of triplicates. 
 
 
4.3 Role of cysteine associated with glutamine and endogenous antioxidant synthesis 
 
4.3.1 CTH, MPST and mTOR gene expression in ES2 cell line 
 
Cysteine is one of the amino acids used in the synthesis of GSH (glutathione). In the 
literatures it is reported that the levels of free cysteine is associated with an increase in 
antioxidative responses and cysteine metabolism. The effects of cysteine exposure in cell 
features and in antioxidative pathways were evaluated. 
The expression of genes involved in cysteine synthesis (CTH), in cysteine degradation 
(MPST) was assessed by RQ-PCR (Figures 18). The assays were performed because was 
observed by NMR (described above) the presence 13C partially labeled GSH (13C labeled glycine 
and 13C labeled glutamate were detected) in cells exposed with 13C glutamine for 30 h. Because of 
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this, it becomes important to understand the behavior of ES2 cells (in glucose privation medium) 
with additional resources of free cysteine.  
In ES2 it was not observed significant differences in CTH expression after cysteine 
supplement, comparing to cells grown in glutamine condition (DMEM without glucose/ with 
glutamine) (Figure 18 a) while in MPST mRNA levels it was verify an increase in cells exposed to 
cysteine supplement (Figure 18 b).  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Because mTOR pathway is sensitive to amino acids, namely glutamine, we evaluate the 
expression of mTOR by RQ-PCR, in ES2 cells grown in glutamine in the presence and absence 
of glutamine. Few differences were detected in glutamine and in cysteine condition (Figure 19). 
Although, with 6 h of exposition the mTOR mRNA levels were lightly increased with cysteine 
supplementation whereas when cells were exposed to cysteine for 30 h the mRNA levels were 
increased in glutamine condition (Figure 19).  
Figure 18- Relative gene expression of CTH (a) and MPST (b). Cells were grown in control and in cysteine condition. HPRT 
gene was used as endogenous control. Expression levels were normalized to those obtained for cells grown in control conditions. 
Data are mean ± error bars of triplicates. *p≤0.05 
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Figure 19- Relative gene expression of mTOR. Cells were grown in control and in cysteine condition. HPRT gene 
was used as endogenous control. Expression levels were normalized to those obtained for cells grown in control 
conditions. Data are mean ± error bars of triplicates. 
 
 
4.3.2 Activity of CTH and MPST promoters in ES2 cell line 
To evaluate the role of cysteine in the activity of CTH and MPST promoter, cells were 
grown in glutamine and glutamine plus cysteine conditions. Cells were transfected with different 
constructs using cationic liposome (Lipofectamine) and then, promoter activity was detected 
using the Dual Luciferase Assay System. 
CTH promoter showed identical luciferase activity in glutamine plus cysteine condition, 
comparatively to glutamine condition being the same verified in MPST promoters (Figure 19). 
Although, these results showed that CTH promoter was about 5 fold more active than MPST 
promoter, in ES2 cell line (Figure 20). 
 
 
 
Figure 20- Luciferase activity of CTH and MPST constructs in transfected ES2 cells. Cells were grown in 
glutamine and cysteine condition. Data are mean ± error bars of triplicates 
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4.4 Role of cysteine in cell migration, cell cycle and apoptosis in ES 2 cell line 
 
4.4.1 Cell migration - In vitro wound healing assay  
In vitro wound healing assay was performed to evaluate the additional effect of cysteine in 
the migration rate of ES2 cells grown in glutamine. The migration rate was evaluated at the 
following time points: 0, 8, 24 and 32 h (Figure 21).  
It was verified a higher cell migration rate in cells grown in glutamine plus cysteine 
condition, comparing to glutamine condition (Figure 22).  
 
 
 
 
 
 
 
 
 
 
4.4.2 Cell cycle analysis by Flow Cytometry 
Figure 21 - In vitro Wound Healing assay in ES2 cells. Comparison between cells cultured in glutamine and in 
cysteine supplement conditions at 0, 8, 24 and 32 h. Phase microscopy (original magnification: 200x).   
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Figure 22- Quantification of wound 
closure in ES2 cells. Cells were cultured 
in glutamine and in cysteine supplement 
conditions at 0, 8, 24 and 32 h 
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Cell cycle analysis was performed to evaluate the additional effect of cysteine in cell cycle 
regulation of ES2 cells grown in glutamine.  
In cell cycle analyzes, few differences were detected between glutamine condition and 
cells exposed to cysteine (Figure 23). At time point 30 h there is an increase in the percentage of 
cells in S phase in glutamine plus cysteine condition (glutamine 11.94% and glutamine plus 
cysteine 15.33%). In both conditions, after 48 h it was observed a significant decrease in S phase 
(glutamine condition 4.5% and glutamine plus cysteine condition 5.85 %) that might be related to 
medium depletion (Figure 23). Summing up, in all time points except at 24h, cells grown in the 
presence of glutamine plus cysteine have a slight increase in the percentage of cells dividing (S + 
G2-M phases). 
 
 
Figure 23– Cell cycle analyzes by flow cytometric (PI staining) in ES2 cells. Cells were grown in control and in 
cysteine conditions at 0, 6, 24, 30, 48 and 60 h. Data are means of triplicates. 
 
 
4.4.3 Cell death analysis by Flow Cytometry 
Cell death analysis was performed to evaluate the effect of cysteine in apoptosis and/or 
necrosis regulation in cells grown in glutamine.  
ES2 cells, after 24 h in culture, showed higher percentage of apoptosis (annexin V positive 
cells) in glutamine plus cysteine condition (Figure 24 a). This result was more evident in time 
point 30 h where the percentage of apoptosis was approximately 6 fold higher than in glutamine 
condition (Figure 24 a). It was also detected after 48h in culture, in both conditions, a decrease in 
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the levels of apoptosis, essentially in glutamine condition (Figure 24 a). An identical behavior in 
both conditions was verified in necrosis (PI positive cells) (Figure 24 b). 
 
 
  
 
4.5 Role of cysteine in aminothiols production 
 
4.5.1 High-performance Liquid Chromatography (HPLC) for aminothiols 
detection in ES2 cell line 
 
HPLC was performed to detect thiols levels (cysteine (CYS), homocysteine (HCYS), 
cysteinylglycine (CysGly), glutathione (GSH) and N-Acetyl Cysteine (NAC)), in ES2 cells exposed 
to glutamine plus cysteine condition, comparing to the glutamine condition. 13C GSH partially 
labeled (13C glycine and 13C glutamate labeled) was detected in ES2 cells by NMR (described 
above) and as GSH, an endogenous antioxidant, results, in part, by the degradation of cysteine it 
becomes important to clarify the possible role of cysteine in GSH production. GSH is essential in 
antioxidant defenses, implicated in cancer progression and under normal conditions it maintains 
physiological levels of ROS, preventing cell damage and death. 
Firstly, glutamine and glutamine plus cysteine crude media were analyzed in order to 
understand which thiols were presented initially in crude medium formulation and which of them 
were excreted by cells. By HPLC, we detected the presence of cysteine, HCYS and NAC in both 
crude mediums (Figure 23 a and b, Figure A1 (Appendix II)) although with different levels. In 
a) b) 
Figure 24– Apoptosis and necrosis analyzes by flow cytometric (Annexin V and PI staining) in ES2 cells. Cell 
mortality were analyzed in cells were grown in control and in cysteine conditions at 0, 6, 24, 30, 48 and 60 h. Data are 
means of triplicates ± error bars of triplicates. 
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glutamine condition, cysteine levels was detected, due to the fact that crude medium contain 
approximately 200 µM of cystine, the reduced form of cysteine (Figure 23 a, Figure A1 (Appendix 
II)) while in cysteine supplemented crude medium the supplementation addiction was 402 µM 
resulting in the final levels of free cysteine of about 602 µM (Figure 23 b, Figure A1 (Appendix 
II)).  
Comparing the supernatants of glutamine with glutamine plus cysteine condition (Figure 23 
a and b, Figure A2 and A3 (Appendix II)) the levels of HCYS (retention time - 7.9 min), CysGly 
(retention time – 8.9 min) and GSH (retention time - 12.8 min) were, respectively, 2.5, 3.3 and 3.4 
fold higher in glutamine plus cysteine condition, which is in agreement with the cysteine 
supplement (Figure 23 a and b, Figure A2 and A3 (Appendix II)).  In relation to the NAC presence 
(retention time – 17.9), in glutamine plus cysteine condition the levels were unchanged while in 
glutamine condition it was verified a decrease in NAC levels (Figure 23 a and b, Figure A2 and 
A3 (Appendix II)). 
 
 
 
Figure 25 –Thiols quantification in crude culture medium and supernatant in ES2 cell line.  Cells were grown in 
glutamine (a) and cysteine (b) conditions. 
 
 
In the cell, cysteine levels were almost similar in both conditions whereas CysGly and 
HCYS levels were, respectively, 1.4 and 2.4 fold higher in glutamine plus cysteine condition than 
glutamine (Figure 24, Figure A4 (Appendix II)). In glutamine condition, GSH levels detected were 
1.6 fold higher comparing to glutamine plus cysteine condition (Figure 24, Figure A4 (Appendix 
II)). In both conditions, NAC levels were lower than the limit of HPLC quantification (<0.313 µM).  
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Figure 26 – Aminothiols quantification in ES2 cell line.  Cells were grown in glutamine and cysteine conditions. 
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5. Discussion  
Research in tumor cell metabolism has recently entered in a new age. The metabolic 
alterations in cancer cells compared to normal cell confer a selective advantage for their survival 
and proliferation (Draoui and Feron, 2011).  
Nowadays it is well known that neoplastic cells metabolize abundant glucose to support 
their energetic and anabolic requirements, namely when tumor metabolism switch the glucose 
consumption from oxidative phosphorylation to aerobic glycolysis (Liu et al., 2010; Shapot and 
Blinov, 1974). Those alterations verified in tumors metabolism show the critical relevance of 
understanding the regulation of enzymes implicated in glucose metabolism, anabolism and 
catabolism. The regulation of gluconeogenic enzymes occurs on multiple levels as gene 
expression, posttranslational modifications and allosteric regulation (Xiong et al., 2011).  
Many studies in cancer research have their focus in the identification of genes related to 
human cancers. As several studies had reported that gluconeogenesis is increased in cells 
surrounding tumors to support their glucose requirements is important to understand the 
regulation of gluconeogenic genes in tumor cells when their microenvironment is exposed to 
glucose privation (Feron, 2009; Liu et al., 2010; Shapot and Blinov, 1974; Yalcin et al., 2009) .  
 In the present thesis, at first by NMR we performed a metabolic profile of ovarian cell 
clear carcinoma (ES2) when exposed to 13C-[U]-glutamine, 13C-[U]-lactate and 13C-[U]-butyrate, in 
a glucose privation medium. 13C unlabeled glycogen was detected in 13C butyrate condition (Figure 
9 b) corroborating previous studies in which the OCCC signature was related to intracellular 
glycogen storage in the cytoplasm, in the form of massive aggregation or diffuse distribution 
(Hkaw et al., 1977; Yamaguchi et al., 2010). In NMR analyzes no 13C labeled glucose was 
detected which indicates that cells was not using 13C glutamine, 13C lactate and 13C butyrate as 
gluconeogenesis substrate. Glutamine appeared to be the major substrate used in glucose 
privation, although our results showed that glutamine was metabolized into TCA 13C labeled 
intermediates instead of be used as gluconeogenic substrate (Figure 10).  
In order to evaluate the expression of key genes involved in gluconeogenesis, ES2 cells in 
glucose privation medium were exposed to different substrates: lactate, glutamine, glucose and 
butyrate.  
Lactate is considered as an alternative metabolic fuel for cancer cells, that often reduce 
pyruvate, the last glycolytic metabolite, to lactate. In some tumors, lactate is also produced in 
response to genetic features of tumors and to stimuli from the surrounding tumor 
microenvironment (Draoui and Feron, 2011; Xiong et al., 2011). Glutamine is the most abundant 
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amino acid in the plasma and can support essential requests for tumor cells proliferation, the 
bioenergetics needs (ATP production) and macromolecules synthesis. Identically to glucose 
consume, tumor cells in culture metabolize glutamine in higher rates than others amino acids 
(DeBerardinis and Cheng, 2010). Butyrate is a short chain fatty acid that can also act as a histone 
deacetylase (HDAC) inhibitor, acting as an epigenetic modulator. Increase in butyrate levels 
active the expression of several genes (as p53 and methylase inhibitory genes), sustaining 
tumorigenesis process (Israël and Schwartz, 2011b). Moreover, Serpa et al., 2010 had reported 
that tumor cells that are able to metabolize butyrate, in a butyrate-rich microenvironment, are 
phenotypically more aggressive.  
 Regarding the expression of phosphoenolpyruvate carboxykinase cytosolic (PCK1) and 
mitochondrial (PCK2) that catalyze the rate-limiting reaction in gluconeogenesis, our results are 
not in agreement with previous studies that correlate the induction of PCK1 mRNA levels with an 
increase in protein levels (Blouin et al., 2010). We verified that the higher increase in PCK1 
mRNA levels, compared to control, was observed when cells were exposed to glucose and 
butyrate (Figure 11). Although the protein levels of glucose and butyrate conditions was, 
respectively, slightly higher and equal to the protein levels detected in control condition (Figure 12 
a). The increase in mRNA levels in butyrate (Figure 11) can be related to the role of butyrate as 
HDAC inhibitior, which can induce an increase in gene transcription. In lactate and glutamine 
condition the opposite was verified, PCK1 mRNA levels were lower than control (Figure 11) 
whereas PCK1 protein levels were approximately 2 fold higher than control (Figure 12 a).  
Extracellular levels of nutrient regulate PCK1 expression activating its acetylation which is 
a major post-translational modifier responsible for metabolic enzyme regulation, acting through 
protein degradation. In normal cells, glucose increase PCK1 acetylation while amino acids that 
can serve as gluconeogenic precursors decrease PCK1 acetylation. PCK1 acetylation correlates 
directly with decreases in PCK1 protein levels, having no direct effect on PCK1 enzymatic activity 
(Blouin et al., 2010; Weickert and Pfeiffer, 2006; Xiong et al., 2011). In our case, acetylation could 
be responsible for results observed in ES2 cell line, where higher levels of PCK1 mRNA 
expression in glucose and butyrate conditions was not reflected in higher PCK1 protein levels 
(Figure 11 and 12 a). This decrease in protein levels occurs maybe because acetylation promotes 
PCK1 ubiquitination and degradation, in both conditions.  
Lactate and glutamine can server as gluconeogenic precursor and, as referred, 
gluconeogenic precursors decrease PCK1 acetylation. As observed in ES2 cell line, an increase 
in PCK1 protein levels comparing to control (Figure 12 a) could be explained by a decline in 
PCK1 acetylation and consequently reflected in an increase in PCK1 protein levels. In lactate 
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condition was also detected a higher activity in luciferase activity of PCK1 promoter construct, 
comparing to control (Figure 14).  
 In the literature, PCK2 was described as constitutively expressed, remaining relatively 
unaltered although their expression is more suited to gluconeogenesis from lactate (Hanson, 
2009; Hanson and Garber, 1972). Our results also support these evidences, we observed an 
increase in PCK2 mRNA expression in lactate condition, comparing to PCK1 mRNA levels 
(Figure 11). This result was also obtained in luciferase activity of PCK2 promoter that showed 
higher activity than PCK1 promoter (Figure 14).  Although, the evaluation luciferase activity of 
promoter is an artificial assay that has to be complemented with functional assays, as chromatin 
immunoprecipitation (ChIP) or electrophoretic mobility shift assay (EMSA).  
Fructose-1,6-bisphosphatase (FBP1) is a gluconeogenic enzyme responsible for the 
irreversible reaction of fructose-2,6-biphosphatase (F1,6BP) into fructose-6-phosphate (F6P). In 
the literature, it was described that in gastric, liver and colon cancer this key enzyme is silenced 
by promoter methylation (Gerhäuser, 2012; Quintas et al., 2008a).  Several studies reported that 
FBP1 is commonly downregulated in cancer cells due to the significant increase in methylation of 
FBP1 gene promoter (Chen et al., 2011). Gerhäuser, 2012 demonstrate in gastric cancer that 
when FBP1 expression is restored by promoter demethlyation, the cell cycle is arrested. 
However, in cancer cells any study in this field was performed under glucose privation 
microenvironment.  
In the present thesis, we observed that ES2 cells need to modify their endogenous 
metabolism in order to supply metabolic requirements. We observed in all conditions, essentially 
in lactate condition and in contrast with the literature, that FBP1 protein levels were upregulated 
(Figure 12 b) under glucose privation, as well as luciferase activity of FBP1 promoter (Figure 14).  
ES2 results obtained under glucose privation (Figure 12 b and 14) may be related to the 
fact that cells in culture need to increase their levels of glucose production. Glucose is an 
essential nutrient for cancer cells because is the initial substrate of glycolysis. In cancer cells, in 
normal growing conditions FBP1 antagonizes glycolysis and as previously described, high rates 
of glycolysis are a metabolic characteristic of cancer cells that justifies the downregulation of 
FBP1 in tumors (Chen et al., 2011; Liu et al., 2010). However, in our case the high levels of FBP1 
expression is essential for glucose synthesis that subsequently will serve as aerobic glycolysis 
substrate and support cancer metabolism.  
 PFKFB is an enzyme associated with the promotion of glycolysis and the inhibition of 
gluconeogenesis through the activation or inhibition, respectively, of their kinase activity (Noguchi 
et al., 2013). The molecular function of PFKFB is to synthesize F 2, 6 BP from F6P. Fructose-2, 
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6-bisphosphatase (PFKFB1) activates 6-phosphofructo-1-kinase (PFK1), an essential and 
irreversible enzyme on controlling the glycolytic pathway (Yalcin et al., 2009).    
 PFKFB have four isozymes (PFKFB 1-4) with high sequence homology in their catalytic 
domains, although with different regulatory and kinetic properties. Previous studies in four 
isoforms had demonstrated that when organs were exposed to hypoxia it’s verified an increase in 
PFKFB mRNA levels. However, PFKFB3 mRNA demonstrated the highest induction in several 
organs as lungs, liver, kidney, brain, heart and testis while PFKFB1 is mainly expressed in liver 
(Yalcin et al., 2009). PFKFB3 expression was also detected in proliferating tissues and 
transformed cells of various tumors (Bartrons and Caro, 2007).  
In the present thesis the PFKFB1 isoform was evaluated since it is the isoform up 
regulated in the liver, and as it was mentioned before OCCC has the up regulation of HNF1 , a 
liver specific gene. Previous studies had reported that an increased in PFKFB3 expression favors 
the progression of aerobic glycolysis, however as in our work ES2 cells were in glucose 
conditioned microenvironment, cells have the need to increase their glucose levels by favoring 
gluconeogenesis and inhibiting aerobic glycolysis.   
In ES2 cell line we verified that the levels of PFKFB1 mRNA in glutamine and lactate 
conditions remains, respectively, lower and almost equal to control condition while in butyrate it 
was detected an increase in PFKFB1 mRNA levels (Figure 11). In luciferase activity of PFKFB1 
promoter, lactate condition induced a luciferase activity approximately 14 fold higher than control 
whereas glutamine and butyrate condition the luciferase activity decreased in comparison to 
control (Figure 14). Although, as gene expression are subject to posttranslational modifications 
and epigenetic regulation, PFKFB1 mRNA levels and luciferase activity of PFKFB1 promoter 
activity was not reflected in protein levels, being PFKFB1 protein expression almost equivalent 
and lower in all conditions (Figure 12 c).  
Furthermore, our results suggest that when cells were in glucose privation the levels of 
PFKFB1 remains lower (Figure 12) in order to stimulate gluconeogenesis. As consequence of an 
increase in stimulatory gluconeogenic enzymes (Figure 12 a and b) and a decrease in inhibitory 
enzymes (Figure 12 c), the glucose synthesis by gluconeogenesis is favored to support the 
metabolic requirements for cancer cell survival.  
Alanine also can be a gluconeogenic substrate, through transamination that coffers the 
conversion of alanine into pyruvate. This reaction catalyzed by alanine aminotransaminase (ALT), 
which expression was evaluated. It was observed an increase in ALT mRNA levels in glucose, 
lactate and glutamine conditions (Figure 13) although as glutamine condition NMR analyzes 
showed the presence of alanine 13C labeled (Figure 10) we also detect the ALT expression with 
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30 hours of glutamine exposure, suggesting that alanine may play an important role as 
gluconeogenic precursor.  
 After the evaluation of gluconeogenic genes expression in cells when exposed to 
different substrates (glucose, glutamine, lactate and butyrate) with previous glucose privation, the 
evaluation of migration rate and cell cycle were performed. In wound healing assay, glucose, 
butyrate and glutamine condition appeared to be more favorable to cell migration, compared to 
control (Figure 16) which can correspond to a more invasive phenotype. 
 Our results in cell cycle analyze showed that butyrate and glutamine conditions were 
more favorable to cell cycle progression (Figure 17 b and d). In those conditions, an increase of 
cell percentage in S and G2-M phases indicates an increase in the rate of DNA synthesis and 
mitosis, meaning the stimulation of cell cycle progression. Previous studies reported that the 
donation of the amido nitrogen from glutamine to nucleotides might become essential during the 
cell cycle, since it occurs transient increases in nucleotide biosynthesis, sustaining the in an 
enhanced proliferation (Braga-Neto et al., 2008; DeBerardinis and Cheng, 2010). Contrary to our 
findings, in fibroblasts butyrate inhibited cell cycle progression (Chang et al., 2012). However 
observations made by Serpa et al., 2010 demonstrate that colon cancer cells that metabolize 
butyrate showed a more aggressive fenotype, associated with a high proliferative rate and a more 
in vivo metastatic behavior. We saw by NMR that ES2 cell are able to metabolize butyrate, at 
least in part, favoring cell cycle progression and migration (Figure 16 and 17 d).  
ES2 results also showed that in glutamine condition the mRNA levels of gluconeogenic 
enzymes remain relatively lower than control (Figure 11) being the same verified in luciferase 
activity of promoter constructs (Figure 14). Although, cells exposed to glutamine had higher cell 
migration (Figure 15 and 16) and cell cycle progression favored (Figure 17 b). Glutamine seems 
to promote cell cycle progression and proliferation. Results obtained also confirm that glutamine 
instead of being used as gluconeogenic precursor was metabolized by another pathway, the 
glutaminolysis.  
Our observations in ES2 cells are in agreement with other studies saying that glutamine 
metabolism is one of the major component of metabolic phenotype of proliferating tumor cells, 
showing that proliferative cells display an intense appetite for glutamine consumption 
(DeBerardinis and Cheng, 2010).  An increase in glutamine metabolism or glutaminolysis is 
associated with carcinogenesis. Inside cell, glutamine is metabolized into glutamate which 
generates NAD+ (essential for glycolysis). Then, glutamate enter in TCA cycle by their 
conversion into -Ketoglutarate ( -KG), providing NADH, nitrogen and carbon skeletons, 
essential for cell proliferation  (Dang, 2012; Israël and Schwartz, 2011a; Matés et al., 2013) 
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As described above, NMR analyzes in ES2 cells (Figure 9 and 11) also proves that 
glutamine was metabolized. The TCA intermediates as aspartate, glutamate and lactate were 13C 
labeled, as well as, intermediates for macromolecules synthesis as alanine, proline and formate 
(Figure 10). The NMR results also detected intracellular 13C labeled GSH, in the glycine and 
glutamate moiety, but not in the cysteine moiety of GSH (Figure 11).  The NMR results also 
detected intracellular 13C labeled GSH as well as 13C labeled glycine (Figure 10) which allowed, 
in part, the formation of GSH metabolite. 
Recent studies have demonstrated that GSH levels play an important role in endogenous 
antioxidant defenses, implicated in cancer progression. GSH allows the maintenance of the redox 
state of cells, drug detoxification and prevention of cellular damage by free radicals, peroxides 
and toxins (Singh et al., 2012; Traverso et al., 2013). Alterations in cysteine and GSH levels are 
considered relevant in cancer development and progression. Mani et al., (2011) described that it 
is common in cancer patients a decrease in cysteine and GSH plasma levels, preceded by loss of 
body weight (cachexia) which compromise the quality of life and increases patients morbidity and 
mortality. At a molecular level, alterations in cysteine and GSH levels could be correlated with an 
oxidative shift in plasma redox state of cells reflected by a decrease ratio of reduced/oxidized 
cysteine form (Mani et al., 2011; Tozer et al., 2008).  
As several in vitro and in vivo studies demonstrated, cysteine is as a rate-limiting factor 
for GSH synthesis (Mani et al., 2011), in the present work it is also evaluated the possible role of 
cysteine supplementation in ES2 cell line and their effect in proliferation, evasion and intracelular 
antioxidant levels.  
In order to evaluate the role of cysteine metabolism in ES2 cells exposed to glutamine in 
the presence or absence of cysteine, gene expression of cystathionine gamma-lyase (CTH) 
(Figure 18 a), assessed by RQ- PCR, was evaluated as well as CTH promoter activity (Figure 
20). CTH, a pyridoxal 5’-phosphate dependent enzyme, is responsible for cysteine production 
under transsulfuration pathway where methionine, an essential amino acid, is catabolized into 
cysteine. CTH is also able to degradate cysteine, leading to pyruvate production (Steegborn, 
1999). Thus, evaluation of CTH becomes important because, as referred, CTH is involved in 
cysteine metabolism and had been reported that CTH deficiency leads to a decrease in cysteine, 
GSH, taurine and hydrogen sulfide (H2S) levels. Mani et al., 2011 described that the treatment of 
hepatocytes with 2 mM propargylglycine (PPG), an irreversible inhibitor of CTH activity, was 
responsible for the decrease of cysteine and GSH levels in 89% and 93%, respectively.  
It was verified, in ES2 cell line, that CTH gene expression (Figure 18 a) and promoter 
activity (Figure 20) of CTH were identical in glutamine and glutamine plus cysteine conditions, 
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allowing to speculate that CTH activity is independent of extracellular levels of cysteine. In the 
literature many authors try to clarify the relationship between cysteine supplementation and CTH 
activity, although this subject has been unclear, in part because the most studies only had 
focused in CTH elimination or inhibition, without considering the exogenous uptake of cysteine 
(Mani et al., 2011). Moreover, CTH has two different and contradictory enzymatic activities since 
it is able to catalyze both cysteine synthesis and degradation (Steegborn, 1999).  
As described, CTH activity plays an essential role in cysteine synthesis and decreases in 
CTH activity have also influence in the reduction of H2S levels, very important for many 
physiological functions as vasorelaxation, stimulation of cellular bioenergetics and promotion of 
angiogenesis (Szabo et al., 2013) . 
Studies developed by Szabo et al., (2013) reported that in colorectal carcinoma lower 
levels of H2S were associated with a decrease in cell proliferation, migration and invasion. 
Although we have not measure H2S, in cell cycle analyzes by flow cytometric (Figure 23), few 
differences in both conditions were detected (Figure 18 a) perhaps by the fact that CTH 
expression is identical in glutamine and glutamine plus cysteine conditions, which can reflect in 
identical H2S levels in both conditions.  
It was also observed that CTH gene expression increase their modulation over the 
course of the experiment (Figure 18 a). Extracellular cysteine resources in culture medium were 
consumed by the cells, although when cysteine levels in culture becomes limited cells had to 
development an alternative way to increase the intracellular levels of cysteine.  
MPST activity, responsible for cysteine degradation was as expected increased in 
glutamine plus cysteine condition (Figure 18 b).  
In the present work the analysis of mTOR pathway (Figure 19) also becomes important 
because this regulatory-associated protein complex was activated in part by amino acids and 
oxidative stress. Glutamine plays an important role in mTOR activation due to the fact that 
glutamine export allows leucine import, responsible for mTOR activation and consequently an 
increase in cell metabolism, survival and proliferation (Fuchs and Bode, 2005; Laplante et al., 
2010).  Comparing glutamine to glutamine plus cysteine condition there was no significant 
differences (Figure 19) indicating that cysteine do not have influence in mTOR pathway.  
The GSH levels and their precursors were assessed by HPLC, allowing the association 
between extracellular cysteine levels and the endogenous antioxidant potential of ES2 cell line 
(Figure 25 and 26).  
Cystine, the reduced form of cysteine, is composed by two cysteine molecules joined by 
a disulfide bond and as referred in results (specification in section 4.5.1) the media formulation 
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contains by 200 µM of cystine. Cystine levels where responsible for cysteine detection in 
glutamine crude culture medium (Figure 25 a). Zhang et al., (2012) described that cystine can 
enter in cell by the association with glutamate. In ES2 cells was detected by NMR (Figure 10) the 
presence of glutamate 13C labeled, resultant from glutamine metabolism. Thereafter, cystine and 
glutamate could be conjugated in γ-Glumate-Cystine, allowing cystine entry, by Xc-transporter, 
into the cell and their posterior conversion in cysteine (Pompella et al., 2006; Zhang et al., 2012). 
In the literature, GSH is described as essential in eliminating ROS such as hydrogen 
peroxide and other organic peroxide, essential in many antioxidant defenses systems. GSH also 
forming conjugates with electrophilic xenobiotics and is associated with the storage and cysteine 
transport, participating in many metabolic processes (Traverso et al., 2013; Wang et al., 1997).  
Oxidative stress has been implicated in cancer development and progression in many 
studies having their focus in GSH synthesis and release. GSH system is a possible target for 
medical intervention against cancer progression  and chemoresistance  (Traverso et al., 2013).  
Increased in GSH levels is a normal response to cysteine supplement, and some 
previous studies in cancer patients have reported and associated the decrease in intracellular 
cysteine levels with a decrease in GSH synthesis (Mani et al., 2011). In ES2 cell line, we 
observed that cysteine supplement led to an increase in GSH synthesis (Figure 25 and 26), 
corroborating the observations made in patients, where lower cysteine levels were associated 
with lower GSH levels.  
Increase in GSH levels is associated with a proliferative response and is essential for cell 
cycle progression, however the molecular mechanism of GSH modulation remains largely 
speculative. In many tumor types high GSH levels were observed, promoting chemotherapy 
resistance.  Increases in GSH levels are typically associated with an increase in GSH-related 
enzymes, such as γ-glutamylcysteine ligase (GCL) and γ-glutamyl-transpeptidades (GGT) 
activites, as well as a higher expression of GSH-transporting export pumps (Traverso et al., 
2013).  
GGT is a cell surface enzyme involved in GSH homeostasis which affect intracellular and 
extracellular microenvironment. In tumors, the GGT activity is significantly higher than normal 
cells, increasing and affecting GSH efflux. This phenomenon have been observed in cancer of 
ovary, colon, liver and leukemias, affecting cell sensitivity to anticancer drugs and increased 
tumor progression and invasion (Pompella et al., 2006). Corti et al., (2010) observed in in vivo 
and in vitro assays performed in melanomas cells that an increased in GGT expression is 
followed by an increase in tumor invasion. In human breast cancer, GGT overexpression and an 
increase in GSH efflux was associated in an unfavorable prognosis (Bard et al., 1986). 
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As referred, ES2 cells in glutamine plus cysteine condition had higher GSH efflux, 
comparing to glutamine condition (Figure 25 and 26). This phenomenon could be associated with 
a decrease in methionine influx. Rao et al., (1990) observed the effects of this essential amino 
acid when freshly isolated hepatocytes incubated with L-[35S] methionine and observed an 
increase in intracellular levels of 35S-labeled cysteine and GSH. We speculate that methionine, 
present in the formulation of crude medium in glutamine and cysteine conditions, could be 
responsible for the inhibition of GSH efflux, in ES2 cell line. Cells with cysteine supplement have 
less methionine requirements for cysteine synthesis by CTH. This fact decrease influx of 
methionine in cysteine condition, remaining methionine levels lower than glutamine condition and 
consequently the inhibition of GSH efflux was lower in glutamine (Figure 25 and 26).  
Due to this fact, cells cultured in glutamine had an increase in intracellular levels of 
methionine, responsible for an inhibition of GSH efflux (Figure 25 and 26). These observations 
was also showed by Wang et al., (1997), who had reported that intracellular GSH levels were 
lower in cells treated with lower concentrations of methionine. Roh et al., (2012) also detected 
that an increase in methionine influx induced an increase of GSH intracellular levels. The 
inhibition of GSH efflux by the levels of methionine was also verified in HeLa cells (Meredith et al., 
1998).   
GSH efflux was also considered as a saturable process regulated in part by positive 
feedback (more extracellular GSH levels, more GSH efflux). As referred, GSH is released by cells 
through GGT-mediated metabolism which is implicated in tumor development in vivo where the 
increase in GSH efflux is associated with an increased invasive behavior  (Traverso et al., 2013). 
In vitro, in ES2 cell line, the same phenomenon was observed in wound healing assay (Figure 21 
and 22), where cells in glutamine plus cysteine condition presented more GSH extracellular levels 
(Figure 25 and 26), and an increase in the migration rate. 
Homocysteine (HCYS) levels, a cysteine precursor in transsulfuration pathway, which is 
synthesized from methionine and further catabolized to cysteine, was increased in glutamine 
condition (Figure 25 a).  This fact occurs because cells that do not have cysteine supplement 
suffer an increase in cysteine synthesis, comparing to glutamine plus cysteine condition, 
originates an increase in cysteine intermediates, namely HCYS (Figure 25 a).  N-acetyl cysteine 
(NAC), commonly present in medium formulation, serves as cysteine source. NAC could be 
internalized by cells, being transformed into cysteine inside cells. In ES2 cell line, as glutamine 
present less cysteine sources, NAC levels in supernatant were lower, comparing to cysteine 
condition (Figure 25 a), due to cysteine requirements for cell survival.  
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 GSH levels also can be associated with changes in cell viability, observed in cysteine and 
glutamine conditions. In ES2 cell line it was verified a decrease in cell viability in cysteine 
condition (Figure 24). This fact can be explained by a decrease in intracellular GSH levels (Figure 
25), because GSH affects significantly cell survival by inhibiting apoptosis through mechanisms 
that do not involve directly ROS modulation. Activity of GGT may contribute to modulate the 
apoptotic process, due to the fact that GGT overexpression induces and increases in GSH 
release for extracellular medium, leading to a decrease in intracellular GSH levels (Corti et al., 
2010).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
 
6. Conclusions 
 Nowadays it is known that cell proliferation is sustained by an adapted tumor cell 
metabolism, favoring carbon and energy demanding, being relevant for tumor progression and 
metastasis. During this thesis we tried to clarify in an ovary cell clear carcinoma in vitro model 
(ES2) if gluconeogenesis is a source of glucose supply as well as the role of amino acid 
metabolism.  
 NMR analyzes in ES2 cell line revealed that glucose is not synthesized from the tested 
compounds. Nevertheless NMR assay showed that glutamine was the major substrate used for 
sustain carbon and energy demands. It was verified that glutaminolysis was responsible for the 
incorporation of glutamine into TCA intermediates that are canalized directly into oxidative 
metabolism leading to energy production and precursors for macromolecules synthesis, essential 
to support metabolic requirements for tumor progression. In NMR analyzes it was also detected 
the presence of not labeled glycogen, characteristic of OCCC. 
 NMR analysis did not show glucose and/or glycogen 13C labeled in the tested cell culture 
conditions maybe because: 1) glucose is a very labile nutrient; 2) other carbon sources can be 
preferentially used; 3) gluconeogenesis is not occuring, or 4) the timepoints evalued are not long 
enough to occur glycogen turnover. 
 However, the evaluation of gluconeogenic genes (PCK1, PCK2, FBP1 and PFKFB1) 
expression was more favorable for glucose using lactate as substrate. Butyrate condition showed 
higher mRNA levels and lower proteins levels that can be related to the role of butyrate as HDAC 
inhibitor, increasing transcription. Contrary to verified in normal cells, the glucose did not acts by 
negative feedback since we verified that the increased glucose levels also stimulate the 
expression of gluconeogenic enzymes. 
 As referred above, we detected by NMR that glutaminolysis lead to the production of 
amino acids as glycine and glutamate and consequently GSH. The additional stimulation of cells 
with cysteine (also a substrate for GSH synthesis) leads to an increase in GSH levels, with a 
concomitant increase in cell proliferation, cell cycle progression and migration. 
 Our findings suggest that glutaminolysis is a central metabolic pathway. In our in vitro 
model of OCCC glutaminolysis seem to be relevant not only for carbon and energy supply but 
also for sustain favorable redox potential through GSH synthesis. GSH synthesis is also favored 
by the additional exposure to cysteine. 
 Summing up, amino acid metabolism can be crucial for OCCC tumorigenesis and drug 
resistance.  
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7. Future Perspectives   
 To better understand the regulatory molecular mechanism of gluconeogenesis, as future 
perspectives, it would be important to investigate the enzymatic activity of gluconeogenic 
enzymes, in order to determinate the functional relevance of gluconeogenic pathway in OCCC. 
The evaluation of mechanisms of regulation of gluconeogenic gene expression must be 
completed with ChiP and/or EMSA.  
 As glutamine revealed to be a key amino acid in tumor metabolism, we ought to 
determine which transporters are mediating glutamine uptake.  
The confirmation that glutamine activates mTOR pathway must be addressed by 
analyzing the phosphorylation levels of mTOR. 
In order to clarify the role of amino acids metabolism in GSH increase and consequent 
drug resistance, we must evaluate ES2 cell line the effect of convential chemotherapy (ie cis-
platin and paclitaxel) in cell viability and DNA demage in the presence of glutamine and/or 
cysteine. Other cell lines from ovarian carcinomas must be also tested. 
The evaluation of H2S production must be quantified in order to confirm the association 
with cell proliferation and migration.  
 Overall, we must validate our findings in animal models, in order to confirm the 
physiopathological relevance of amino acid metabolism in tumor growth and metastasis as well 
as in drug resistance.  
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Appendix I 
 
Solutions prepared for the experimental work:  
 
Luria-Bertani (LB) medium (Sambrook & Russel, 2001) 
 
For 1L:  
10g Tryptone (L42, Oxoid) 
5g Yeast extract (403 687, Cultimed) 
10g NaCl (106404, Merck) 
ddH2O to 1L 
 
10X PBS (pH 7.4-7.6) (Sambrook & Russel, 2001) 
 
For 1L: 
80g NaCl (1.37M) (106404, Merck) 
2g KH2PO4 (14.7mM) (104873, Merck) 
11.1g Na2HPO4 (78.1mM) (S-0876, Sigma) 
2g KCl (26.8mM) (104936, Merck) 
ddH2O to 1L 
 
10X TBS (pH 7.4-7.6)  
 
For 1L:  
8g NaCl (106404, Merck) 
0.63g Tris (15504-038, Gibco BRL) 
4.4 mL hydrochloric acid (1M)  
ddH2O to 1L  
 
5X SDS gel loading buffer (Sambrook & Russel, 2001) 
 
250 mM Tris HCl (pH 6.8) (0.5M 161-0799, Bio-rad) 
10% SDS (V6551, Promega) 
0.5% bromophenol blue 
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50% glycerol (1.04094.1000, Merck) 
 
Transfer buffer  
 
For 5L: 
75g glycine (US16407, USB) 
15g Trizma-base (T-8524, Sigma)  
ddH2O to 4L 
1L Metanol (107018, Merck) 
5mL 10% SDS (V6551, Promega) 
 
15% resolving gel and 5% stacking gel for Tris-glycine SDS-
Polyacrylamide Gel Electrophoresis prepared accordingly to 
Sambrook & Russel, 2001 
 
PBS 0.1% (v/v) Tween 20 
 
For 1L: 
1mL Tween 20 (20605, USB) 
1X PBS to 1L 
 
PBS 0.2% (w/v) BSA  
 
0.4g BSA (A9647, Sigma) 
200 mL 1X PBS 
 
PBS 0.2% (w/v) BSA 0.1% (v/v) Triton X-100 
 
For 4mL: 
3.96 mL PBS 0.2% (w/v) BSA  
40 µL 10% Triton X-100 diluted in ddH2O (100% Triton X-100, T8787, 
Sigma) 
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5% (w/v) skim milk in PBS 0.1% (v/v) Tween 20 
 
5g skim milk (Molico, Nestlé) 
100 mL PBS 0.1% (v/v) Tween 20 
 
RIPA buffer 
 
For 10 mL: 
20 mM Tris-HCl pH 7.5 
150 mM NaCl (106404, Merck) 
5mM KCl (104936, Merck) 
5mM MgCl2 (M-8266, Sigma) 
1% Triton X-100 (T8787, Sigma) 
ddH2O to 10 mL 
1 Complete, Mini, EDTA-free Protease Inhibitor Cocktail Tablet 
(11836170001, Roche) 
1 mM Orthovanadate (Na3VO4) 
1 mM Sodium fluoride (NaF) (201154, Sigma) 
 
 
50 µg/mL Propidium Iodide (PI) solution – Cell cyle assay 
 
For 50 mL: 
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS) 
49 mL 1X PBS 
0.1 mg/mL RNase A (Easy spin kit, Citomed) 
0.05% Triton X-100 (T8787, Sigma) 
 
50 µg/mL Propidium Iodide (PI) solution – Apoptosis assay 
 
For 50 mL: 
1 mL of 2.5 mg/mL PI solution (P4170, Sigma) (prepared in 1X PBS) 
49 mL 1X PBS 
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Annexin binding buffer 1X 
 
0.01 M Hepes (pH 7.4) (391333, Millipore) 
0.14 M NaCl (106404, Merck) 
2.5 mM CaCl2 (449709, Sigma) 
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Appendix II 
 
 
Figure A1: HPLC spectrum in control crude medium and in cysteine crude medium.  
Control is referent to glutamine condition whereas cysteine is referent to glutamine plus cysteine. 
 
 
 
 
Figure A2 - HPLC spectrum in control crude medium and supernatant..  
Control is referent to glutamine condition. 
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Figure A3– HPLC spectrum in cysteine crude medium and supernatant.  
Cysteine is referent to glutamine plus cysteine.    
 
 
 
Figure A4- HPLC spectrum of intracellular contents in control and cysteine condition. 
Control is referent to glutamine condition whereas cysteine is referent to glutamine plus cysteine.    
